data_2mvh_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mvh _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 . . . . . 0 N--CA 1.467 0.408 0 CA-C-O 120.929 0.395 . . . . 1.0 110.524 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.3 t -62.0 -18.61 61.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.271 0.557 . . . . 1.0 110.258 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.464 ' C ' ' H ' ' A' ' 8' ' ' LEU . 3.9 mp -79.6 138.04 20.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.105 -0.952 . . . . 1.0 108.995 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -77.44 23.73 0.21 Allowed 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.865 -0.42 . . . . 1.0 109.865 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.464 ' H ' ' C ' ' A' ' 6' ' ' ILE . 2.5 pp -54.39 167.97 0.51 Allowed Pre-proline 0 N--CA 1.445 -0.698 0 CA-C-N 116.279 -0.419 . . . . 1.0 111.335 -179.288 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.5 ' CD ' ' H ' ' A' ' 10' ' ' LYS . 89.2 Cg_endo -92.42 -49.09 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.359 0 C-N-CA 122.271 1.981 . . . . 1.0 108.663 178.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . 0.5 ' H ' ' CD ' ' A' ' 9' ' ' PRO . 59.1 pttt -173.4 32.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 114.649 -1.159 . . . . 1.0 108.313 177.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -49.79 -73.44 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 115.228 -0.896 . . . . 1.0 111.381 -178.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' A' ' 16' ' ' VAL . 96.4 mt -63.31 -38.42 91.1 Favored 'General case' 0 C--O 1.211 -0.934 0 N-CA-C 108.639 -0.874 . . . . 1.0 108.639 178.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.15 -51.9 28.98 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.031 -0.532 . . . . 1.0 113.149 -177.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -79.54 -37.66 23.07 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.654 -0.578 . . . . 1.0 111.654 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.6 mt -76.2 -56.39 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 112.199 0.444 . . . . 1.0 112.199 -178.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.459 ' N ' ' O ' ' A' ' 12' ' ' LEU . 0.8 OUTLIER -54.91 -31.63 25.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 120.763 -0.375 . . . . 1.0 111.059 -176.911 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.1 mmt180 -66.5 -35.19 79.64 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 108.318 -0.993 . . . . 1.0 108.318 177.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.05 -39.44 94.08 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.661 -0.7 . . . . 1.0 109.43 178.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.8 mmt -60.33 -48.11 83.14 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.557 -0.747 . . . . 1.0 109.559 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.51 -42.06 87.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 114.682 -1.145 . . . . 1.0 109.7 179.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.8 -23.2 63.04 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.57 -1.012 . . . . 1.0 110.57 179.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.8 m -90.27 -27.32 19.54 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 121.145 0.498 . . . . 1.0 109.662 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -69.88 -49.59 50.79 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 115.456 -0.793 . . . . 1.0 110.235 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 . . . . . 0 CA--C 1.536 0.405 0 CA-C-N 115.101 -0.954 . . . . 1.0 112.181 179.122 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 42.3 p90 . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.987 0.422 . . . . 1.0 110.251 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 68.8 p -129.32 -6.12 4.81 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-O 122.066 0.936 . . . . 1.0 108.873 178.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.458 ' C ' ' H ' ' A' ' 8' ' ' LEU . 5.6 mt -76.51 145.84 9.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 113.68 -1.6 . . . . 1.0 108.821 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 62.3 mttp -78.47 23.81 0.29 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 109.855 -0.424 . . . . 1.0 109.855 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.458 ' H ' ' C ' ' A' ' 6' ' ' ILE . 2.0 pp -55.06 169.09 0.45 Allowed Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 122.921 0.489 . . . . 1.0 111.813 -178.503 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -106.26 65.29 0.02 OUTLIER 'Trans proline' 0 N--CA 1.487 1.145 0 C-N-CA 123.576 2.85 . . . . 1.0 110.429 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 99.6 mttt 55.14 54.05 9.34 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 116.335 -0.393 . . . . 1.0 110.465 -178.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -56.01 -76.63 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.246 0.546 . . . . 1.0 110.372 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.452 ' O ' ' N ' ' A' ' 16' ' ' VAL . 95.7 mt -66.67 -37.37 84.63 Favored 'General case' 0 C--O 1.21 -1.003 0 CA-C-N 115.323 -0.853 . . . . 1.0 108.939 179.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.36 -44.54 44.81 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 121.358 -0.448 . . . . 1.0 112.687 -178.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.65 -43.0 8.02 Favored Glycine 0 CA--C 1.53 0.996 0 N-CA-C 111.521 -0.631 . . . . 1.0 111.521 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.6 mt -73.88 -53.59 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 N-CA-C 112.284 0.476 . . . . 1.0 112.284 -178.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.452 ' N ' ' O ' ' A' ' 12' ' ' LEU . 0.5 OUTLIER -57.89 -30.46 38.26 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.665 0 N-CA-C 109.925 -0.398 . . . . 1.0 109.925 -177.374 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 26.3 tpt180 -62.43 -39.31 92.92 Favored 'General case' 0 CA--C 1.518 -0.273 0 N-CA-C 108.595 -0.891 . . . . 1.0 108.595 177.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.99 -40.08 94.4 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 115.471 -0.786 . . . . 1.0 109.418 179.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 21.9 mmt -61.59 -44.09 97.65 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.53 -0.759 . . . . 1.0 110.361 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.1 mt -65.33 -42.79 92.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.423 -0.808 . . . . 1.0 111.174 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.38 -29.76 72.39 Favored Glycine 0 N--CA 1.462 0.419 0 N-CA-C 110.143 -1.183 . . . . 1.0 110.143 179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.5 m -78.06 -49.19 14.44 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 121.518 0.675 . . . . 1.0 109.4 178.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -64.32 -73.02 0.13 Allowed 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 114.864 -1.062 . . . . 1.0 110.811 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 45.4 ptt85 . . . . . 0 N--CA 1.483 1.178 0 C-N-CA 123.788 0.835 . . . . 1.0 112.867 -179.901 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.458 ' O ' ' OG1' ' A' ' 5' ' ' THR . 0.5 OUTLIER . . . . . 0 N--CA 1.473 0.69 0 N-CA-C 111.752 0.279 . . . . 1.0 111.752 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.458 ' OG1' ' O ' ' A' ' 4' ' ' TYR . 24.9 p 66.32 14.83 9.87 Favored 'General case' 0 N--CA 1.466 0.347 0 O-C-N 123.818 0.699 . . . . 1.0 110.991 -178.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.442 ' C ' ' H ' ' A' ' 8' ' ' LEU . 22.7 mt -121.96 138.39 52.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 108.115 -1.068 . . . . 1.0 108.115 179.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -75.32 23.0 0.11 Allowed 'General case' 0 N--CA 1.469 0.501 0 O-C-N 122.41 -0.181 . . . . 1.0 110.962 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.442 ' H ' ' C ' ' A' ' 6' ' ' ILE . 2.8 pp -58.31 167.65 1.59 Allowed Pre-proline 0 CA--C 1.545 0.758 0 C-N-CA 122.309 0.244 . . . . 1.0 111.24 -179.458 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_endo -106.37 67.02 0.02 OUTLIER 'Trans proline' 0 N--CA 1.49 1.32 0 C-N-CA 123.648 2.898 . . . . 1.0 110.774 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 68.1 mttm 54.36 54.83 8.87 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 121.068 0.461 . . . . 1.0 110.188 -178.444 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -54.33 -83.4 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 115.869 -0.605 . . . . 1.0 110.889 -179.071 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 94.7 mt -60.79 -33.61 73.24 Favored 'General case' 0 C--O 1.214 -0.787 0 N-CA-C 109.111 -0.7 . . . . 1.0 109.111 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.36 -43.14 43.45 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.601 -0.599 . . . . 1.0 111.601 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -84.4 -48.96 4.84 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 112.067 -0.413 . . . . 1.0 112.067 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 3.5 mp -70.28 -46.6 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 112.645 0.609 . . . . 1.0 112.645 -177.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.4 p -56.82 -30.98 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 C-N-CA 120.042 -0.663 . . . . 1.0 111.005 -176.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -65.96 -36.1 82.39 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.315 -0.994 . . . . 1.0 108.315 177.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.28 -39.56 94.93 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.677 -0.692 . . . . 1.0 109.601 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 9.3 mmt -60.38 -48.54 81.32 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 115.759 -0.655 . . . . 1.0 109.91 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 98.1 mt -66.17 -42.67 88.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.731 -1.122 . . . . 1.0 110.268 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.32 -26.22 65.88 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.358 -1.097 . . . . 1.0 110.358 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -88.0 -39.43 14.69 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.257 0.551 . . . . 1.0 110.416 179.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -64.6 -48.26 75.58 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.347 -0.842 . . . . 1.0 111.504 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 39.7 mtm180 . . . . . 0 CA--C 1.539 0.543 0 CA-C-N 115.71 -0.677 . . . . 1.0 112.034 -179.875 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 27.4 m-85 . . . . . 0 N--CA 1.472 0.639 0 N-CA-C 110.189 -0.301 . . . . 1.0 110.189 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.3 p 57.37 20.55 6.02 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 115.476 -0.783 . . . . 1.0 111.046 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.401 ' C ' ' H ' ' A' ' 8' ' ' LEU . 28.0 mt -124.12 134.45 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 CA-C-N 114.548 -1.205 . . . . 1.0 107.754 179.465 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -76.41 38.85 0.19 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.753 0.311 . . . . 1.0 110.719 -178.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.439 HD13 ' H ' ' A' ' 10' ' ' LYS . 0.4 OUTLIER -70.58 169.0 15.61 Favored Pre-proline 0 CA--C 1.548 0.893 0 CA-C-N 116.522 -0.308 . . . . 1.0 111.765 -178.747 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -106.81 56.88 0.01 OUTLIER 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 123.847 3.031 . . . . 1.0 108.038 176.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . 0.439 ' H ' HD13 ' A' ' 8' ' ' LEU . 62.9 mttp 62.96 48.12 4.04 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 114.662 -1.154 . . . . 1.0 110.268 -177.155 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -64.51 -70.12 0.24 Allowed 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.276 0.56 . . . . 1.0 110.271 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 86.7 mt -62.36 -33.69 75.21 Favored 'General case' 0 C--O 1.212 -0.883 0 CA-C-N 115.41 -0.814 . . . . 1.0 109.131 179.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -48.88 -53.5 17.77 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 121.281 -0.485 . . . . 1.0 113.193 -177.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.56 -40.28 11.2 Favored Glycine 0 N--CA 1.47 0.964 0 CA-C-N 117.529 0.665 . . . . 1.0 111.758 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.8 mt -71.12 -51.27 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 N-CA-C 112.363 0.505 . . . . 1.0 112.363 -177.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.6 p -56.33 -30.56 30.74 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.538 0 C-N-CA 120.331 -0.548 . . . . 1.0 110.655 -177.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 18.8 mmm180 -65.23 -36.67 84.86 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.377 -0.971 . . . . 1.0 108.377 177.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.78 -39.19 93.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.257 -0.883 . . . . 1.0 109.635 179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.9 mmt -60.8 -45.8 93.01 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.639 -0.71 . . . . 1.0 109.867 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.9 mt -65.23 -42.2 93.62 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 114.802 -1.09 . . . . 1.0 110.533 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.4 -31.68 70.74 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 109.971 -1.252 . . . . 1.0 109.971 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.5 t -73.1 -37.31 66.78 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.487 0.66 . . . . 1.0 109.715 178.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -59.4 -48.59 81.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 114.746 -1.116 . . . . 1.0 111.421 -178.097 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 10.3 ptp85 . . . . . 0 N--CA 1.471 0.623 0 CA-C-O 120.839 0.352 . . . . 1.0 110.475 179.756 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 41.8 p90 . . . . . 0 N--CA 1.467 0.381 0 CA-C-O 121.068 0.461 . . . . 1.0 110.469 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 81.3 p -129.0 11.97 6.1 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.325 -0.852 . . . . 1.0 108.77 178.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.464 ' C ' ' H ' ' A' ' 8' ' ' LEU . 7.4 mt -102.18 142.93 15.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.208 -1.36 . . . . 1.0 108.969 -178.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -66.68 11.32 0.1 Allowed 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 111.937 0.347 . . . . 1.0 111.937 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.464 ' H ' ' C ' ' A' ' 6' ' ' ILE . 3.6 pp -58.01 169.93 0.8 Allowed Pre-proline 0 CA--C 1.538 0.503 0 CA-C-O 119.539 -0.267 . . . . 1.0 111.221 -179.145 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.438 ' CG ' ' H ' ' A' ' 10' ' ' LYS . 83.9 Cg_endo -96.73 -63.12 0.01 OUTLIER 'Trans proline' 0 N--CA 1.489 1.224 0 C-N-CA 122.752 2.301 . . . . 1.0 109.17 178.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . 0.438 ' H ' ' CG ' ' A' ' 9' ' ' PRO . 54.2 mtmt -157.75 36.68 0.26 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 107.908 -1.145 . . . . 1.0 107.908 178.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 23.0 t80 -48.44 -75.14 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.561 -0.745 . . . . 1.0 111.464 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.47 ' O ' ' N ' ' A' ' 16' ' ' VAL . 90.9 mt -65.0 -38.93 92.57 Favored 'General case' 0 C--O 1.211 -0.943 0 N-CA-C 108.803 -0.814 . . . . 1.0 108.803 179.178 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.42 -50.95 33.72 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 121.313 -0.47 . . . . 1.0 112.874 -178.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.71 -38.81 26.74 Favored Glycine 0 CA--C 1.529 0.942 0 N-CA-C 111.685 -0.566 . . . . 1.0 111.685 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.78 -57.33 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 122.571 0.349 . . . . 1.0 111.895 -178.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.47 ' N ' ' O ' ' A' ' 12' ' ' LEU . 0.5 OUTLIER -55.13 -30.45 24.18 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 C-N-CA 120.962 -0.295 . . . . 1.0 110.542 -177.274 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 25.0 tpt180 -64.68 -39.45 93.69 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 108.466 -0.939 . . . . 1.0 108.466 177.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.21 -39.76 93.85 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.112 -0.949 . . . . 1.0 109.741 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.4 mmt -60.43 -47.76 84.7 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.667 -0.697 . . . . 1.0 109.669 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.4 mt -66.02 -42.18 89.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.669 -1.151 . . . . 1.0 110.027 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -60.99 -25.85 64.78 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.413 -1.075 . . . . 1.0 110.413 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.4 m -87.87 -35.3 17.83 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.253 0.549 . . . . 1.0 110.093 179.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -66.58 -49.07 67.59 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.361 -0.836 . . . . 1.0 111.378 -178.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.7 mtp85 . . . . . 0 CA--C 1.537 0.445 0 CA-C-N 115.839 -0.619 . . . . 1.0 111.594 -179.944 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 75.5 m-85 . . . . . 0 N--CA 1.465 0.32 0 N-CA-C 109.7 -0.481 . . . . 1.0 109.7 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.1 p -65.12 -10.0 27.28 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.56 -0.746 . . . . 1.0 110.087 -179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.458 ' C ' ' H ' ' A' ' 8' ' ' LEU . 3.8 mp -98.1 138.73 21.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 114.924 -1.034 . . . . 1.0 109.665 -179.331 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 61.0 pttt -67.52 9.16 0.27 Allowed 'General case' 0 CA--C 1.535 0.366 0 CA-C-N 116.352 -0.385 . . . . 1.0 111.18 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.458 ' H ' ' C ' ' A' ' 6' ' ' ILE . 3.1 pp -48.61 165.48 0.25 Allowed Pre-proline 0 CA--C 1.543 0.704 0 N-CA-C 112.349 0.5 . . . . 1.0 112.349 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.508 ' CD ' ' H ' ' A' ' 10' ' ' LYS . 49.7 Cg_endo -95.39 -51.41 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.364 0 C-N-CA 122.97 2.447 . . . . 1.0 109.393 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . 0.508 ' H ' ' CD ' ' A' ' 9' ' ' PRO . 60.3 pttt -167.58 32.01 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 114.972 -1.013 . . . . 1.0 108.64 178.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 40.6 t80 -55.66 -73.12 0.06 Allowed 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.185 -0.916 . . . . 1.0 111.357 -178.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.469 ' O ' ' N ' ' A' ' 16' ' ' VAL . 92.9 mt -63.29 -38.85 92.76 Favored 'General case' 0 C--O 1.211 -0.932 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 179.288 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.12 -52.62 26.3 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 121.243 -0.503 . . . . 1.0 112.818 -177.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.09 -39.34 27.66 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.686 -0.566 . . . . 1.0 111.686 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.6 mt -76.01 -56.85 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 112.357 0.503 . . . . 1.0 112.357 -178.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' A' ' 12' ' ' LEU . 0.8 OUTLIER -53.99 -31.4 21.06 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.464 0 CA-C-O 121.148 0.499 . . . . 1.0 110.889 -177.279 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 59.8 ttt85 -67.33 -36.62 81.82 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 108.392 -0.966 . . . . 1.0 108.392 178.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.22 -39.52 94.86 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.046 -0.979 . . . . 1.0 109.466 179.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 9.8 mmt -60.11 -48.58 81.11 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.646 0.736 . . . . 1.0 109.568 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.0 mt -66.41 -41.66 88.97 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.411 -1.268 . . . . 1.0 109.795 179.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -74.21 -5.32 71.16 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.437 -0.801 . . . . 1.0 111.948 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 38.6 t -93.59 -30.94 14.72 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 121.716 0.769 . . . . 1.0 108.957 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.95 -45.78 33.22 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 114.27 -1.332 . . . . 1.0 108.751 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 85.8 mtt-85 . . . . . 0 CA--C 1.535 0.377 0 CA-C-N 114.971 -1.013 . . . . 1.0 112.193 179.65 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 34.3 p90 . . . . . 0 CA--C 1.528 0.126 0 CA-C-O 121.053 0.454 . . . . 1.0 110.833 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 70.6 p -127.03 20.99 6.88 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.802 0.81 . . . . 1.0 109.586 179.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.443 ' C ' ' H ' ' A' ' 8' ' ' LEU . 34.1 mt -113.35 147.65 16.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 114.241 -1.345 . . . . 1.0 109.079 -178.584 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -76.11 21.02 0.18 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-O 120.753 0.311 . . . . 1.0 110.77 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.443 ' H ' ' C ' ' A' ' 6' ' ' ILE . 2.6 pp -59.39 167.25 2.4 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-N 116.302 -0.408 . . . . 1.0 111.503 -179.079 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -105.0 64.73 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 123.532 2.822 . . . . 1.0 110.913 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 97.6 mttt 54.95 55.81 7.33 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.274 0.559 . . . . 1.0 109.733 -178.464 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 12.5 t80 -53.53 -78.79 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.471 -0.786 . . . . 1.0 111.091 -178.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.457 ' O ' ' N ' ' A' ' 16' ' ' VAL . 85.8 mt -65.31 -38.13 89.23 Favored 'General case' 0 C--O 1.211 -0.938 0 N-CA-C 108.357 -0.979 . . . . 1.0 108.357 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.21 -52.67 22.1 Favored Glycine 0 CA--C 1.532 1.12 0 CA-C-N 115.95 -0.568 . . . . 1.0 112.61 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.85 -39.02 25.66 Favored Glycine 0 CA--C 1.531 1.046 0 CA-C-N 117.253 0.526 . . . . 1.0 112.037 179.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.6 mt -75.53 -55.76 10.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 112.042 0.386 . . . . 1.0 112.042 -178.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.457 ' N ' ' O ' ' A' ' 12' ' ' LEU . 0.4 OUTLIER -56.82 -30.0 31.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 120.741 0.305 . . . . 1.0 110.385 -177.202 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 32.7 tpt85 -65.35 -38.79 91.16 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.217 -1.031 . . . . 1.0 108.217 177.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.68 -39.05 92.75 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.273 -0.876 . . . . 1.0 109.592 179.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.6 mmt -60.36 -47.19 87.11 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.462 0.649 . . . . 1.0 109.359 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.8 mt -65.75 -41.6 91.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.806 -1.088 . . . . 1.0 109.584 178.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.35 -24.45 59.13 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.939 -0.865 . . . . 1.0 110.939 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.1 m -87.48 -35.28 18.32 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 121.285 0.564 . . . . 1.0 109.97 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -65.14 -48.53 73.22 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.09 -0.959 . . . . 1.0 111.677 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 42.5 mtm180 . . . . . 0 CA--C 1.537 0.471 0 CA-C-N 115.986 -0.552 . . . . 1.0 111.883 179.524 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.443 ' C ' ' H ' ' A' ' 6' ' ' ILE . 76.3 m-85 . . . . . 0 N--CA 1.464 0.273 0 CA-C-O 121.284 0.564 . . . . 1.0 110.599 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 29.8 p -63.5 -4.64 2.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.224 -0.898 . . . . 1.0 110.393 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.443 ' H ' ' C ' ' A' ' 4' ' ' TYR . 4.2 mp -103.5 137.62 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.125 -0.943 . . . . 1.0 109.299 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -79.24 31.37 0.22 Allowed 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 110.114 -0.328 . . . . 1.0 110.114 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.425 ' H ' ' C ' ' A' ' 6' ' ' ILE . 0.8 OUTLIER -52.95 167.64 0.39 Allowed Pre-proline 0 CA--C 1.549 0.904 0 CA-C-N 116.079 -0.509 . . . . 1.0 111.877 -178.612 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -102.55 5.92 0.44 Allowed 'Trans proline' 0 N--CA 1.487 1.117 0 C-N-CA 123.414 2.743 . . . . 1.0 110.206 179.086 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 25.1 mmtp 122.83 39.97 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 126.969 2.107 . . . . 1.0 107.886 -179.2 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -62.62 -69.15 0.28 Allowed 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.352 -0.84 . . . . 1.0 110.178 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 89.6 mt -63.09 -34.88 78.56 Favored 'General case' 0 C--O 1.211 -0.951 0 N-CA-C 108.898 -0.779 . . . . 1.0 108.898 179.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.36 -52.6 22.97 Favored Glycine 0 CA--C 1.529 0.966 0 CA-C-N 116.116 -0.493 . . . . 1.0 113.13 -177.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -80.77 -39.94 13.07 Favored Glycine 0 CA--C 1.529 0.949 0 CA-C-N 117.491 0.645 . . . . 1.0 111.72 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.1 mt -72.48 -53.21 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 112.393 0.516 . . . . 1.0 112.393 -178.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.3 p -55.28 -30.98 25.87 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 C-N-CA 120.404 -0.518 . . . . 1.0 110.816 -177.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -66.53 -35.63 80.71 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 108.332 -0.988 . . . . 1.0 108.332 177.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.58 -39.36 94.19 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.577 -0.738 . . . . 1.0 109.459 178.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 10.4 mmt -60.18 -46.97 87.9 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.535 -0.757 . . . . 1.0 109.706 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.8 mt -66.27 -42.64 88.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.674 -1.148 . . . . 1.0 109.829 179.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.87 -24.27 64.44 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.43 -1.068 . . . . 1.0 110.43 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -88.83 -29.54 19.62 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.169 0.509 . . . . 1.0 109.855 179.415 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -66.35 -49.79 65.75 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 115.392 -0.822 . . . . 1.0 111.035 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 49.7 mtm-85 . . . . . 0 CA--C 1.535 0.394 0 CA-C-N 115.538 -0.755 . . . . 1.0 111.857 179.88 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 43.0 p90 . . . . . 0 N--CA 1.47 0.558 0 N-CA-C 109.858 -0.423 . . . . 1.0 109.858 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.405 ' C ' ' H ' ' A' ' 7' ' ' LYS . 4.2 t -135.62 -5.03 2.25 Favored 'General case' 0 N--CA 1.48 1.047 0 CA-C-O 121.972 0.892 . . . . 1.0 108.989 179.029 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.8 mt -68.29 -3.89 2.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 113.89 -1.505 . . . . 1.0 109.867 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.405 ' H ' ' C ' ' A' ' 5' ' ' THR . 48.4 mttt 52.36 30.03 7.59 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 114.867 -1.06 . . . . 1.0 109.257 -179.533 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -61.63 169.14 2.67 Favored Pre-proline 0 N--CA 1.443 -0.82 0 CA-C-N 113.406 -1.725 . . . . 1.0 111.705 -178.05 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -105.4 63.58 0.02 OUTLIER 'Trans proline' 0 N--CA 1.482 0.821 0 C-N-CA 123.569 2.846 . . . . 1.0 108.898 176.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt 58.26 45.82 16.61 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 115.299 -0.864 . . . . 1.0 111.01 -178.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -64.32 -73.8 0.11 Allowed 'General case' 0 N--CA 1.472 0.669 0 CA-C-O 121.301 0.572 . . . . 1.0 109.688 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 87.3 mt -64.14 -34.59 78.41 Favored 'General case' 0 C--O 1.214 -0.774 0 CA-C-N 115.291 -0.868 . . . . 1.0 109.141 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -48.49 -50.15 24.97 Favored Glycine 0 CA--C 1.528 0.897 0 CA-C-N 116.153 -0.476 . . . . 1.0 112.814 -177.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.22 -41.93 9.01 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 117.468 0.634 . . . . 1.0 112.072 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 91.2 mt -72.05 -49.73 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 112.845 0.683 . . . . 1.0 112.845 -177.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.4 p -55.38 -32.33 29.18 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.474 0 C-N-CA 120.45 -0.5 . . . . 1.0 111.1 -176.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 87.4 mtm180 -65.57 -35.2 80.15 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 108.31 -0.996 . . . . 1.0 108.31 177.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.01 -39.13 93.82 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.525 -0.761 . . . . 1.0 109.304 179.24 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.6 mmt -60.77 -46.61 89.8 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.646 -0.706 . . . . 1.0 109.759 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.3 mt -65.52 -41.91 92.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 114.591 -1.186 . . . . 1.0 110.313 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.62 -27.92 61.96 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 110.401 -1.08 . . . . 1.0 110.401 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.2 t -73.24 -35.61 66.28 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.896 0.855 . . . . 1.0 109.257 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -61.07 -40.3 93.15 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.225 -1.352 . . . . 1.0 110.969 -178.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 24.0 mmm180 . . . . . 0 N--CA 1.469 0.486 0 CA-C-N 116.214 -0.448 . . . . 1.0 110.627 -178.755 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 36.3 p90 . . . . . 0 C--O 1.222 -0.382 0 CA-C-O 119.899 -0.096 . . . . 1.0 110.988 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.1 t 44.32 42.77 5.52 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 114.265 1.209 . . . . 1.0 114.265 178.058 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.416 ' C ' ' H ' ' A' ' 8' ' ' LEU . 29.6 mt -133.78 144.49 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.781 -1.192 . . . . 1.0 107.781 179.22 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -72.84 17.48 0.12 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.063 0.394 . . . . 1.0 112.063 -178.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.416 ' H ' ' C ' ' A' ' 6' ' ' ILE . 2.7 pp -62.08 168.84 3.32 Favored Pre-proline 0 CA--C 1.543 0.707 0 C-N-CA 122.862 0.465 . . . . 1.0 110.648 -179.679 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -104.21 64.1 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.373 0 C-N-CA 123.475 2.784 . . . . 1.0 111.802 -179.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 16.1 ttmm 58.31 54.91 5.35 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-O 121.174 0.511 . . . . 1.0 110.481 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -59.93 -79.04 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 115.54 -0.754 . . . . 1.0 110.96 -179.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.418 ' O ' ' N ' ' A' ' 16' ' ' VAL . 86.0 mt -65.1 -37.74 88.44 Favored 'General case' 0 C--O 1.212 -0.868 0 CA-C-N 115.576 -0.738 . . . . 1.0 109.015 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.85 -45.85 40.33 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-N 115.997 -0.547 . . . . 1.0 112.688 -178.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.45 -41.34 9.19 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 111.607 -0.597 . . . . 1.0 111.607 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.4 mt -74.07 -54.85 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 112.121 0.415 . . . . 1.0 112.121 -178.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.418 ' N ' ' O ' ' A' ' 12' ' ' LEU . 0.7 OUTLIER -56.65 -31.3 34.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.102 0.477 . . . . 1.0 110.703 -177.114 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -65.52 -37.05 85.62 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.66 -0.867 . . . . 1.0 108.66 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.84 -40.07 96.33 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.022 -0.99 . . . . 1.0 109.24 178.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.1 mmt -60.57 -47.26 86.99 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.519 -0.764 . . . . 1.0 109.81 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.0 mt -65.84 -40.57 91.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 114.68 -1.145 . . . . 1.0 109.989 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.24 -26.92 59.64 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.726 -0.949 . . . . 1.0 110.726 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.9 m -87.42 -43.2 12.26 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 121.193 0.52 . . . . 1.0 110.344 179.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -66.75 -49.11 67.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.407 -0.815 . . . . 1.0 111.19 -178.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 52.9 mtp180 . . . . . 0 CA--C 1.535 0.395 0 CA-C-N 115.315 -0.857 . . . . 1.0 111.917 179.726 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.5 ttt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 108.931 -0.766 . . . . 1.0 108.931 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -62.61 -44.73 95.55 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.073 -0.512 . . . . 1.0 109.964 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.409 ' CD2' ' O ' ' A' ' 4' ' ' TYR . 75.6 t80 -164.3 153.0 13.12 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.028 -0.533 . . . . 1.0 109.66 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.409 ' O ' ' CD2' ' A' ' 3' ' ' PHE . 90.0 m-85 -75.44 127.43 33.11 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.929 0.395 . . . . 1.0 110.524 -179.698 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.3 t -62.0 -18.61 61.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.271 0.557 . . . . 1.0 110.258 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.464 ' C ' ' H ' ' A' ' 8' ' ' LEU . 3.9 mp -79.6 138.04 20.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.105 -0.952 . . . . 1.0 108.995 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -77.44 23.73 0.21 Allowed 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.865 -0.42 . . . . 1.0 109.865 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.464 ' H ' ' C ' ' A' ' 6' ' ' ILE . 2.5 pp -54.39 167.97 0.51 Allowed Pre-proline 0 N--CA 1.445 -0.698 0 CA-C-N 116.279 -0.419 . . . . 1.0 111.335 -179.288 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.5 ' CD ' ' H ' ' A' ' 10' ' ' LYS . 89.2 Cg_endo -92.42 -49.09 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.359 0 C-N-CA 122.271 1.981 . . . . 1.0 108.663 178.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . 0.5 ' H ' ' CD ' ' A' ' 9' ' ' PRO . 59.1 pttt -173.4 32.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 114.649 -1.159 . . . . 1.0 108.313 177.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -49.79 -73.44 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 115.228 -0.896 . . . . 1.0 111.381 -178.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' A' ' 16' ' ' VAL . 96.4 mt -63.31 -38.42 91.1 Favored 'General case' 0 C--O 1.211 -0.934 0 N-CA-C 108.639 -0.874 . . . . 1.0 108.639 178.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.15 -51.9 28.98 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.031 -0.532 . . . . 1.0 113.149 -177.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -79.54 -37.66 23.07 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.654 -0.578 . . . . 1.0 111.654 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.6 mt -76.2 -56.39 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 112.199 0.444 . . . . 1.0 112.199 -178.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.459 ' N ' ' O ' ' A' ' 12' ' ' LEU . 0.8 OUTLIER -54.91 -31.63 25.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 120.763 -0.375 . . . . 1.0 111.059 -176.911 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.1 mmt180 -66.5 -35.19 79.64 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 108.318 -0.993 . . . . 1.0 108.318 177.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.05 -39.44 94.08 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.661 -0.7 . . . . 1.0 109.43 178.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.8 mmt -60.33 -48.11 83.14 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.557 -0.747 . . . . 1.0 109.559 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.51 -42.06 87.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 114.682 -1.145 . . . . 1.0 109.7 179.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.8 -23.2 63.04 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.57 -1.012 . . . . 1.0 110.57 179.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.8 m -90.27 -27.32 19.54 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 121.145 0.498 . . . . 1.0 109.662 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -69.88 -49.59 50.79 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 115.456 -0.793 . . . . 1.0 110.235 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 46.94 79.49 0.06 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.101 -0.954 . . . . 1.0 112.181 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 64.7 tttp -62.34 -44.79 95.65 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.303 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 50.5 p-10 . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.816 -1.088 . . . . 1.0 110.284 179.868 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.1 ptt? . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 108.906 -0.775 . . . . 1.0 108.906 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -166.05 131.03 2.32 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.669 -0.493 . . . . 1.0 109.669 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -79.15 -174.2 3.99 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.299 0.571 . . . . 1.0 110.981 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 42.3 p90 -154.08 159.48 41.54 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.406 -0.815 . . . . 1.0 110.251 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 68.8 p -129.32 -6.12 4.81 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-O 122.066 0.936 . . . . 1.0 108.873 178.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.458 ' C ' ' H ' ' A' ' 8' ' ' LEU . 5.6 mt -76.51 145.84 9.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 113.68 -1.6 . . . . 1.0 108.821 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 62.3 mttp -78.47 23.81 0.29 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 109.855 -0.424 . . . . 1.0 109.855 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.458 ' H ' ' C ' ' A' ' 6' ' ' ILE . 2.0 pp -55.06 169.09 0.45 Allowed Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 122.921 0.489 . . . . 1.0 111.813 -178.503 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -106.26 65.29 0.02 OUTLIER 'Trans proline' 0 N--CA 1.487 1.145 0 C-N-CA 123.576 2.85 . . . . 1.0 110.429 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 99.6 mttt 55.14 54.05 9.34 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 116.335 -0.393 . . . . 1.0 110.465 -178.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -56.01 -76.63 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.246 0.546 . . . . 1.0 110.372 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.452 ' O ' ' N ' ' A' ' 16' ' ' VAL . 95.7 mt -66.67 -37.37 84.63 Favored 'General case' 0 C--O 1.21 -1.003 0 CA-C-N 115.323 -0.853 . . . . 1.0 108.939 179.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.36 -44.54 44.81 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 121.358 -0.448 . . . . 1.0 112.687 -178.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.65 -43.0 8.02 Favored Glycine 0 CA--C 1.53 0.996 0 N-CA-C 111.521 -0.631 . . . . 1.0 111.521 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.6 mt -73.88 -53.59 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 N-CA-C 112.284 0.476 . . . . 1.0 112.284 -178.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.452 ' N ' ' O ' ' A' ' 12' ' ' LEU . 0.5 OUTLIER -57.89 -30.46 38.26 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.665 0 N-CA-C 109.925 -0.398 . . . . 1.0 109.925 -177.374 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 26.3 tpt180 -62.43 -39.31 92.92 Favored 'General case' 0 CA--C 1.518 -0.273 0 N-CA-C 108.595 -0.891 . . . . 1.0 108.595 177.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.99 -40.08 94.4 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 115.471 -0.786 . . . . 1.0 109.418 179.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 21.9 mmt -61.59 -44.09 97.65 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.53 -0.759 . . . . 1.0 110.361 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.1 mt -65.33 -42.79 92.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.423 -0.808 . . . . 1.0 111.174 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.38 -29.76 72.39 Favored Glycine 0 N--CA 1.462 0.419 0 N-CA-C 110.143 -1.183 . . . . 1.0 110.143 179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.5 m -78.06 -49.19 14.44 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 121.518 0.675 . . . . 1.0 109.4 178.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -64.32 -73.02 0.13 Allowed 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 114.864 -1.062 . . . . 1.0 110.811 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 45.4 ptt85 29.05 46.9 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.788 0.835 . . . . 1.0 112.867 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -62.98 135.19 57.16 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.716 -0.674 . . . . 1.0 110.303 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 53.3 p-10 . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.199 -0.905 . . . . 1.0 110.964 -179.968 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.0 mtt . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 108.978 -0.749 . . . . 1.0 108.978 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -66.58 121.01 14.4 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 109.604 -0.517 . . . . 1.0 109.604 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 52.8 t80 -64.7 -49.77 69.6 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 121.196 0.522 . . . . 1.0 110.412 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.458 ' O ' ' OG1' ' A' ' 5' ' ' THR . 0.5 OUTLIER -72.26 -38.04 68.96 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 115.381 -0.827 . . . . 1.0 111.752 -179.271 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.458 ' OG1' ' O ' ' A' ' 4' ' ' TYR . 24.9 p 66.32 14.83 9.87 Favored 'General case' 0 N--CA 1.466 0.347 0 O-C-N 123.818 0.699 . . . . 1.0 110.991 -178.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.442 ' C ' ' H ' ' A' ' 8' ' ' LEU . 22.7 mt -121.96 138.39 52.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 108.115 -1.068 . . . . 1.0 108.115 179.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -75.32 23.0 0.11 Allowed 'General case' 0 N--CA 1.469 0.501 0 O-C-N 122.41 -0.181 . . . . 1.0 110.962 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.442 ' H ' ' C ' ' A' ' 6' ' ' ILE . 2.8 pp -58.31 167.65 1.59 Allowed Pre-proline 0 CA--C 1.545 0.758 0 C-N-CA 122.309 0.244 . . . . 1.0 111.24 -179.458 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_endo -106.37 67.02 0.02 OUTLIER 'Trans proline' 0 N--CA 1.49 1.32 0 C-N-CA 123.648 2.898 . . . . 1.0 110.774 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 68.1 mttm 54.36 54.83 8.87 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 121.068 0.461 . . . . 1.0 110.188 -178.444 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -54.33 -83.4 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 115.869 -0.605 . . . . 1.0 110.889 -179.071 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 94.7 mt -60.79 -33.61 73.24 Favored 'General case' 0 C--O 1.214 -0.787 0 N-CA-C 109.111 -0.7 . . . . 1.0 109.111 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.36 -43.14 43.45 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.601 -0.599 . . . . 1.0 111.601 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -84.4 -48.96 4.84 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 112.067 -0.413 . . . . 1.0 112.067 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 3.5 mp -70.28 -46.6 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 112.645 0.609 . . . . 1.0 112.645 -177.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.4 p -56.82 -30.98 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 C-N-CA 120.042 -0.663 . . . . 1.0 111.005 -176.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -65.96 -36.1 82.39 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.315 -0.994 . . . . 1.0 108.315 177.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.28 -39.56 94.93 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.677 -0.692 . . . . 1.0 109.601 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 9.3 mmt -60.38 -48.54 81.32 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 115.759 -0.655 . . . . 1.0 109.91 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 98.1 mt -66.17 -42.67 88.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.731 -1.122 . . . . 1.0 110.268 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.32 -26.22 65.88 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.358 -1.097 . . . . 1.0 110.358 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -88.0 -39.43 14.69 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.257 0.551 . . . . 1.0 110.416 179.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -64.6 -48.26 75.58 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.347 -0.842 . . . . 1.0 111.504 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 39.7 mtm180 42.33 -163.65 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.71 -0.677 . . . . 1.0 112.034 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp 55.33 -169.04 0.08 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.228 -0.442 . . . . 1.0 110.708 -179.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 117.97 -1.014 . . . . 1.0 110.408 -179.928 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.1 ttt . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.044 -0.725 . . . . 1.0 109.044 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 62.5 tttp 56.97 90.22 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.124 -0.489 . . . . 1.0 110.79 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.434 ' CD2' ' O ' ' A' ' 3' ' ' PHE . 31.3 p90 -70.51 105.6 3.15 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 116.117 -0.492 . . . . 1.0 110.377 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 27.4 m-85 -73.01 -52.14 15.55 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 116.484 -0.325 . . . . 1.0 110.189 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.3 p 57.37 20.55 6.02 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 115.476 -0.783 . . . . 1.0 111.046 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.401 ' C ' ' H ' ' A' ' 8' ' ' LEU . 28.0 mt -124.12 134.45 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 CA-C-N 114.548 -1.205 . . . . 1.0 107.754 179.465 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -76.41 38.85 0.19 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.753 0.311 . . . . 1.0 110.719 -178.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.439 HD13 ' H ' ' A' ' 10' ' ' LYS . 0.4 OUTLIER -70.58 169.0 15.61 Favored Pre-proline 0 CA--C 1.548 0.893 0 CA-C-N 116.522 -0.308 . . . . 1.0 111.765 -178.747 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -106.81 56.88 0.01 OUTLIER 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 123.847 3.031 . . . . 1.0 108.038 176.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . 0.439 ' H ' HD13 ' A' ' 8' ' ' LEU . 62.9 mttp 62.96 48.12 4.04 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 114.662 -1.154 . . . . 1.0 110.268 -177.155 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -64.51 -70.12 0.24 Allowed 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.276 0.56 . . . . 1.0 110.271 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 86.7 mt -62.36 -33.69 75.21 Favored 'General case' 0 C--O 1.212 -0.883 0 CA-C-N 115.41 -0.814 . . . . 1.0 109.131 179.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -48.88 -53.5 17.77 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 121.281 -0.485 . . . . 1.0 113.193 -177.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.56 -40.28 11.2 Favored Glycine 0 N--CA 1.47 0.964 0 CA-C-N 117.529 0.665 . . . . 1.0 111.758 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.8 mt -71.12 -51.27 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 N-CA-C 112.363 0.505 . . . . 1.0 112.363 -177.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.6 p -56.33 -30.56 30.74 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.538 0 C-N-CA 120.331 -0.548 . . . . 1.0 110.655 -177.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 18.8 mmm180 -65.23 -36.67 84.86 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.377 -0.971 . . . . 1.0 108.377 177.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.78 -39.19 93.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.257 -0.883 . . . . 1.0 109.635 179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.9 mmt -60.8 -45.8 93.01 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.639 -0.71 . . . . 1.0 109.867 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.9 mt -65.23 -42.2 93.62 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 114.802 -1.09 . . . . 1.0 110.533 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.4 -31.68 70.74 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 109.971 -1.252 . . . . 1.0 109.971 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.5 t -73.1 -37.31 66.78 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.487 0.66 . . . . 1.0 109.715 178.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -59.4 -48.59 81.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 114.746 -1.116 . . . . 1.0 111.421 -178.097 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 10.3 ptp85 -80.63 160.21 25.14 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 120.839 0.352 . . . . 1.0 110.475 179.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? -61.65 -48.32 81.37 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.927 -0.768 . . . . 1.0 108.927 -179.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.6 t70 . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 117.994 -1.003 . . . . 1.0 110.092 179.295 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 81.6 mtp . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 108.921 -0.77 . . . . 1.0 108.921 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -62.71 -41.97 99.41 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.137 -0.483 . . . . 1.0 110.062 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -78.14 -176.34 4.54 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.053 -0.521 . . . . 1.0 110.311 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -158.21 161.48 37.8 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 115.756 -0.656 . . . . 1.0 110.469 178.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 81.3 p -129.0 11.97 6.1 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.325 -0.852 . . . . 1.0 108.77 178.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.464 ' C ' ' H ' ' A' ' 8' ' ' LEU . 7.4 mt -102.18 142.93 15.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.208 -1.36 . . . . 1.0 108.969 -178.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -66.68 11.32 0.1 Allowed 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 111.937 0.347 . . . . 1.0 111.937 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.464 ' H ' ' C ' ' A' ' 6' ' ' ILE . 3.6 pp -58.01 169.93 0.8 Allowed Pre-proline 0 CA--C 1.538 0.503 0 CA-C-O 119.539 -0.267 . . . . 1.0 111.221 -179.145 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.438 ' CG ' ' H ' ' A' ' 10' ' ' LYS . 83.9 Cg_endo -96.73 -63.12 0.01 OUTLIER 'Trans proline' 0 N--CA 1.489 1.224 0 C-N-CA 122.752 2.301 . . . . 1.0 109.17 178.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . 0.438 ' H ' ' CG ' ' A' ' 9' ' ' PRO . 54.2 mtmt -157.75 36.68 0.26 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 107.908 -1.145 . . . . 1.0 107.908 178.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 23.0 t80 -48.44 -75.14 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.561 -0.745 . . . . 1.0 111.464 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.47 ' O ' ' N ' ' A' ' 16' ' ' VAL . 90.9 mt -65.0 -38.93 92.57 Favored 'General case' 0 C--O 1.211 -0.943 0 N-CA-C 108.803 -0.814 . . . . 1.0 108.803 179.178 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.42 -50.95 33.72 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 121.313 -0.47 . . . . 1.0 112.874 -178.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.71 -38.81 26.74 Favored Glycine 0 CA--C 1.529 0.942 0 N-CA-C 111.685 -0.566 . . . . 1.0 111.685 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.78 -57.33 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 122.571 0.349 . . . . 1.0 111.895 -178.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.47 ' N ' ' O ' ' A' ' 12' ' ' LEU . 0.5 OUTLIER -55.13 -30.45 24.18 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 C-N-CA 120.962 -0.295 . . . . 1.0 110.542 -177.274 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 25.0 tpt180 -64.68 -39.45 93.69 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 108.466 -0.939 . . . . 1.0 108.466 177.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.21 -39.76 93.85 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.112 -0.949 . . . . 1.0 109.741 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.4 mmt -60.43 -47.76 84.7 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.667 -0.697 . . . . 1.0 109.669 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.4 mt -66.02 -42.18 89.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.669 -1.151 . . . . 1.0 110.027 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -60.99 -25.85 64.78 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.413 -1.075 . . . . 1.0 110.413 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.4 m -87.87 -35.3 17.83 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.253 0.549 . . . . 1.0 110.093 179.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -66.58 -49.07 67.59 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.361 -0.836 . . . . 1.0 111.378 -178.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.7 mtp85 50.34 -161.64 0.06 Allowed 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.839 -0.619 . . . . 1.0 111.594 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 31.3 mtmm 53.58 91.63 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.08 -0.509 . . . . 1.0 111.08 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 51.9 p-10 . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 117.983 -1.008 . . . . 1.0 110.337 -179.986 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 72.8 mtp . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 108.888 -0.782 . . . . 1.0 108.888 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -65.38 -8.32 17.98 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.863 -0.608 . . . . 1.0 110.539 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -62.8 114.8 3.84 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-O 120.881 0.372 . . . . 1.0 110.264 -179.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 75.5 m-85 -85.89 140.0 30.76 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.981 -0.554 . . . . 1.0 109.7 178.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.1 p -65.12 -10.0 27.28 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.56 -0.746 . . . . 1.0 110.087 -179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.458 ' C ' ' H ' ' A' ' 8' ' ' LEU . 3.8 mp -98.1 138.73 21.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 114.924 -1.034 . . . . 1.0 109.665 -179.331 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 61.0 pttt -67.52 9.16 0.27 Allowed 'General case' 0 CA--C 1.535 0.366 0 CA-C-N 116.352 -0.385 . . . . 1.0 111.18 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.458 ' H ' ' C ' ' A' ' 6' ' ' ILE . 3.1 pp -48.61 165.48 0.25 Allowed Pre-proline 0 CA--C 1.543 0.704 0 N-CA-C 112.349 0.5 . . . . 1.0 112.349 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.508 ' CD ' ' H ' ' A' ' 10' ' ' LYS . 49.7 Cg_endo -95.39 -51.41 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.364 0 C-N-CA 122.97 2.447 . . . . 1.0 109.393 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . 0.508 ' H ' ' CD ' ' A' ' 9' ' ' PRO . 60.3 pttt -167.58 32.01 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 114.972 -1.013 . . . . 1.0 108.64 178.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 40.6 t80 -55.66 -73.12 0.06 Allowed 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.185 -0.916 . . . . 1.0 111.357 -178.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.469 ' O ' ' N ' ' A' ' 16' ' ' VAL . 92.9 mt -63.29 -38.85 92.76 Favored 'General case' 0 C--O 1.211 -0.932 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 179.288 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.12 -52.62 26.3 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 121.243 -0.503 . . . . 1.0 112.818 -177.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.09 -39.34 27.66 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.686 -0.566 . . . . 1.0 111.686 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.6 mt -76.01 -56.85 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 112.357 0.503 . . . . 1.0 112.357 -178.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' A' ' 12' ' ' LEU . 0.8 OUTLIER -53.99 -31.4 21.06 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.464 0 CA-C-O 121.148 0.499 . . . . 1.0 110.889 -177.279 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 59.8 ttt85 -67.33 -36.62 81.82 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 108.392 -0.966 . . . . 1.0 108.392 178.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.22 -39.52 94.86 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.046 -0.979 . . . . 1.0 109.466 179.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 9.8 mmt -60.11 -48.58 81.11 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.646 0.736 . . . . 1.0 109.568 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.0 mt -66.41 -41.66 88.97 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.411 -1.268 . . . . 1.0 109.795 179.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -74.21 -5.32 71.16 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.437 -0.801 . . . . 1.0 111.948 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 38.6 t -93.59 -30.94 14.72 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 121.716 0.769 . . . . 1.0 108.957 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.95 -45.78 33.22 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 114.27 -1.332 . . . . 1.0 108.751 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 85.8 mtt-85 48.34 17.0 0.11 Allowed 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 114.971 -1.013 . . . . 1.0 112.193 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -162.62 132.52 4.5 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.671 0.272 . . . . 1.0 110.442 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 61.3 t0 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.947 -1.025 . . . . 1.0 110.537 -179.776 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.486 ' SD ' ' N ' ' A' ' 1' ' ' MET . 2.2 mpt? . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 108.973 -0.751 . . . . 1.0 108.973 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -75.29 132.5 41.06 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.368 -0.378 . . . . 1.0 110.454 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.494 ' CD1' ' N ' ' A' ' 4' ' ' TYR . 46.3 p90 -143.32 -38.6 0.33 Allowed 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 120.899 0.381 . . . . 1.0 110.048 179.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.494 ' N ' ' CD1' ' A' ' 3' ' ' PHE . 34.3 p90 -62.7 166.14 5.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.02 -0.536 . . . . 1.0 110.833 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 70.6 p -127.03 20.99 6.88 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.802 0.81 . . . . 1.0 109.586 179.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.443 ' C ' ' H ' ' A' ' 8' ' ' LEU . 34.1 mt -113.35 147.65 16.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 114.241 -1.345 . . . . 1.0 109.079 -178.584 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -76.11 21.02 0.18 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-O 120.753 0.311 . . . . 1.0 110.77 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.443 ' H ' ' C ' ' A' ' 6' ' ' ILE . 2.6 pp -59.39 167.25 2.4 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-N 116.302 -0.408 . . . . 1.0 111.503 -179.079 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -105.0 64.73 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 123.532 2.822 . . . . 1.0 110.913 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 97.6 mttt 54.95 55.81 7.33 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.274 0.559 . . . . 1.0 109.733 -178.464 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 12.5 t80 -53.53 -78.79 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.471 -0.786 . . . . 1.0 111.091 -178.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.457 ' O ' ' N ' ' A' ' 16' ' ' VAL . 85.8 mt -65.31 -38.13 89.23 Favored 'General case' 0 C--O 1.211 -0.938 0 N-CA-C 108.357 -0.979 . . . . 1.0 108.357 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.21 -52.67 22.1 Favored Glycine 0 CA--C 1.532 1.12 0 CA-C-N 115.95 -0.568 . . . . 1.0 112.61 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.85 -39.02 25.66 Favored Glycine 0 CA--C 1.531 1.046 0 CA-C-N 117.253 0.526 . . . . 1.0 112.037 179.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.6 mt -75.53 -55.76 10.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 112.042 0.386 . . . . 1.0 112.042 -178.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.457 ' N ' ' O ' ' A' ' 12' ' ' LEU . 0.4 OUTLIER -56.82 -30.0 31.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 120.741 0.305 . . . . 1.0 110.385 -177.202 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 32.7 tpt85 -65.35 -38.79 91.16 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.217 -1.031 . . . . 1.0 108.217 177.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.68 -39.05 92.75 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.273 -0.876 . . . . 1.0 109.592 179.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.6 mmt -60.36 -47.19 87.11 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.462 0.649 . . . . 1.0 109.359 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.8 mt -65.75 -41.6 91.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.806 -1.088 . . . . 1.0 109.584 178.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.35 -24.45 59.13 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.939 -0.865 . . . . 1.0 110.939 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.1 m -87.48 -35.28 18.32 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 121.285 0.564 . . . . 1.0 109.97 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -65.14 -48.53 73.22 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.09 -0.959 . . . . 1.0 111.677 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 42.5 mtm180 44.83 -159.59 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 115.986 -0.552 . . . . 1.0 111.883 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.0 mmtp -66.61 145.62 55.38 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.29 -0.414 . . . . 1.0 110.082 -179.609 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 68.7 m-20 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.035 -0.983 . . . . 1.0 110.726 -179.639 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.2 tpt . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 108.913 -0.773 . . . . 1.0 108.913 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -60.44 140.38 57.26 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 116.132 -0.486 . . . . 1.0 111.056 -179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 43.9 p90 -68.98 154.1 42.66 Favored 'General case' 0 CA--C 1.528 0.111 0 CA-C-N 116.008 -0.542 . . . . 1.0 110.172 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.443 ' C ' ' H ' ' A' ' 6' ' ' ILE . 76.3 m-85 -65.65 137.69 57.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.71 -0.677 . . . . 1.0 110.599 -179.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 29.8 p -63.5 -4.64 2.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.224 -0.898 . . . . 1.0 110.393 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.443 ' H ' ' C ' ' A' ' 4' ' ' TYR . 4.2 mp -103.5 137.62 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.125 -0.943 . . . . 1.0 109.299 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -79.24 31.37 0.22 Allowed 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 110.114 -0.328 . . . . 1.0 110.114 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.425 ' H ' ' C ' ' A' ' 6' ' ' ILE . 0.8 OUTLIER -52.95 167.64 0.39 Allowed Pre-proline 0 CA--C 1.549 0.904 0 CA-C-N 116.079 -0.509 . . . . 1.0 111.877 -178.612 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -102.55 5.92 0.44 Allowed 'Trans proline' 0 N--CA 1.487 1.117 0 C-N-CA 123.414 2.743 . . . . 1.0 110.206 179.086 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 25.1 mmtp 122.83 39.97 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 126.969 2.107 . . . . 1.0 107.886 -179.2 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -62.62 -69.15 0.28 Allowed 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.352 -0.84 . . . . 1.0 110.178 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 89.6 mt -63.09 -34.88 78.56 Favored 'General case' 0 C--O 1.211 -0.951 0 N-CA-C 108.898 -0.779 . . . . 1.0 108.898 179.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.36 -52.6 22.97 Favored Glycine 0 CA--C 1.529 0.966 0 CA-C-N 116.116 -0.493 . . . . 1.0 113.13 -177.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -80.77 -39.94 13.07 Favored Glycine 0 CA--C 1.529 0.949 0 CA-C-N 117.491 0.645 . . . . 1.0 111.72 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.1 mt -72.48 -53.21 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 112.393 0.516 . . . . 1.0 112.393 -178.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.3 p -55.28 -30.98 25.87 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 C-N-CA 120.404 -0.518 . . . . 1.0 110.816 -177.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -66.53 -35.63 80.71 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 108.332 -0.988 . . . . 1.0 108.332 177.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.58 -39.36 94.19 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.577 -0.738 . . . . 1.0 109.459 178.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 10.4 mmt -60.18 -46.97 87.9 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.535 -0.757 . . . . 1.0 109.706 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.8 mt -66.27 -42.64 88.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.674 -1.148 . . . . 1.0 109.829 179.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.87 -24.27 64.44 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.43 -1.068 . . . . 1.0 110.43 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -88.83 -29.54 19.62 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.169 0.509 . . . . 1.0 109.855 179.415 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -66.35 -49.79 65.75 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 115.392 -0.822 . . . . 1.0 111.035 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 49.7 mtm-85 49.53 -178.89 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 115.538 -0.755 . . . . 1.0 111.857 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -65.39 135.96 55.9 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 115.96 -0.564 . . . . 1.0 110.345 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 41.2 p-10 . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 118.041 -0.981 . . . . 1.0 110.764 -179.976 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 43.0 tpp . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.155 -0.683 . . . . 1.0 109.155 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -148.62 145.48 27.79 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 109.451 -0.574 . . . . 1.0 109.451 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -161.23 175.35 12.41 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.016 0.436 . . . . 1.0 110.64 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 43.0 p90 -149.11 161.55 41.74 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.937 -0.574 . . . . 1.0 109.858 179.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.405 ' C ' ' H ' ' A' ' 7' ' ' LYS . 4.2 t -135.62 -5.03 2.25 Favored 'General case' 0 N--CA 1.48 1.047 0 CA-C-O 121.972 0.892 . . . . 1.0 108.989 179.029 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.8 mt -68.29 -3.89 2.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 113.89 -1.505 . . . . 1.0 109.867 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.405 ' H ' ' C ' ' A' ' 5' ' ' THR . 48.4 mttt 52.36 30.03 7.59 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 114.867 -1.06 . . . . 1.0 109.257 -179.533 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -61.63 169.14 2.67 Favored Pre-proline 0 N--CA 1.443 -0.82 0 CA-C-N 113.406 -1.725 . . . . 1.0 111.705 -178.05 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -105.4 63.58 0.02 OUTLIER 'Trans proline' 0 N--CA 1.482 0.821 0 C-N-CA 123.569 2.846 . . . . 1.0 108.898 176.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt 58.26 45.82 16.61 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 115.299 -0.864 . . . . 1.0 111.01 -178.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -64.32 -73.8 0.11 Allowed 'General case' 0 N--CA 1.472 0.669 0 CA-C-O 121.301 0.572 . . . . 1.0 109.688 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 87.3 mt -64.14 -34.59 78.41 Favored 'General case' 0 C--O 1.214 -0.774 0 CA-C-N 115.291 -0.868 . . . . 1.0 109.141 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -48.49 -50.15 24.97 Favored Glycine 0 CA--C 1.528 0.897 0 CA-C-N 116.153 -0.476 . . . . 1.0 112.814 -177.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.22 -41.93 9.01 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 117.468 0.634 . . . . 1.0 112.072 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 91.2 mt -72.05 -49.73 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 112.845 0.683 . . . . 1.0 112.845 -177.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.4 p -55.38 -32.33 29.18 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.474 0 C-N-CA 120.45 -0.5 . . . . 1.0 111.1 -176.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 87.4 mtm180 -65.57 -35.2 80.15 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 108.31 -0.996 . . . . 1.0 108.31 177.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.01 -39.13 93.82 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.525 -0.761 . . . . 1.0 109.304 179.24 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.6 mmt -60.77 -46.61 89.8 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.646 -0.706 . . . . 1.0 109.759 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.3 mt -65.52 -41.91 92.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 114.591 -1.186 . . . . 1.0 110.313 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.62 -27.92 61.96 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 110.401 -1.08 . . . . 1.0 110.401 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.2 t -73.24 -35.61 66.28 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.896 0.855 . . . . 1.0 109.257 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -61.07 -40.3 93.15 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.225 -1.352 . . . . 1.0 110.969 -178.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 24.0 mmm180 -54.08 -38.71 65.6 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.214 -0.448 . . . . 1.0 110.627 -178.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -62.81 136.86 58.08 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 109.798 -0.445 . . . . 1.0 109.798 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.5 t0 . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.847 -1.073 . . . . 1.0 111.051 -179.596 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.6 ttt . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 108.902 -0.777 . . . . 1.0 108.902 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 47.3 mmtm -67.11 131.76 46.46 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 109.571 -0.529 . . . . 1.0 109.571 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.458 ' CD1' ' N ' ' A' ' 4' ' ' TYR . 51.1 p90 -112.45 -42.0 3.76 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 122.84 0.456 . . . . 1.0 110.482 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.458 ' N ' ' CD1' ' A' ' 3' ' ' PHE . 36.3 p90 -66.24 -35.64 80.95 Favored 'General case' 0 C--O 1.222 -0.382 0 CA-C-N 116.367 -0.379 . . . . 1.0 110.988 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.1 t 44.32 42.77 5.52 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 114.265 1.209 . . . . 1.0 114.265 178.058 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.416 ' C ' ' H ' ' A' ' 8' ' ' LEU . 29.6 mt -133.78 144.49 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.781 -1.192 . . . . 1.0 107.781 179.22 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -72.84 17.48 0.12 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.063 0.394 . . . . 1.0 112.063 -178.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.416 ' H ' ' C ' ' A' ' 6' ' ' ILE . 2.7 pp -62.08 168.84 3.32 Favored Pre-proline 0 CA--C 1.543 0.707 0 C-N-CA 122.862 0.465 . . . . 1.0 110.648 -179.679 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -104.21 64.1 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.373 0 C-N-CA 123.475 2.784 . . . . 1.0 111.802 -179.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 16.1 ttmm 58.31 54.91 5.35 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-O 121.174 0.511 . . . . 1.0 110.481 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -59.93 -79.04 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 115.54 -0.754 . . . . 1.0 110.96 -179.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.418 ' O ' ' N ' ' A' ' 16' ' ' VAL . 86.0 mt -65.1 -37.74 88.44 Favored 'General case' 0 C--O 1.212 -0.868 0 CA-C-N 115.576 -0.738 . . . . 1.0 109.015 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.85 -45.85 40.33 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-N 115.997 -0.547 . . . . 1.0 112.688 -178.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.45 -41.34 9.19 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 111.607 -0.597 . . . . 1.0 111.607 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.4 mt -74.07 -54.85 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 112.121 0.415 . . . . 1.0 112.121 -178.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.418 ' N ' ' O ' ' A' ' 12' ' ' LEU . 0.7 OUTLIER -56.65 -31.3 34.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.102 0.477 . . . . 1.0 110.703 -177.114 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -65.52 -37.05 85.62 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.66 -0.867 . . . . 1.0 108.66 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.84 -40.07 96.33 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.022 -0.99 . . . . 1.0 109.24 178.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.1 mmt -60.57 -47.26 86.99 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.519 -0.764 . . . . 1.0 109.81 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.0 mt -65.84 -40.57 91.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 114.68 -1.145 . . . . 1.0 109.989 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.24 -26.92 59.64 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.726 -0.949 . . . . 1.0 110.726 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.9 m -87.42 -43.2 12.26 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 121.193 0.52 . . . . 1.0 110.344 179.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -66.75 -49.11 67.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.407 -0.815 . . . . 1.0 111.19 -178.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 52.9 mtp180 48.38 35.2 5.41 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.315 -0.857 . . . . 1.0 111.917 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 68.3 mttm 53.3 41.51 32.12 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.24 -0.436 . . . . 1.0 111.106 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 36.6 t70 . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.209 -0.901 . . . . 1.0 110.421 179.942 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 . . . . . 0 N--CA 1.467 0.408 0 CA-C-O 120.929 0.395 . . . . 1.0 110.524 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.3 t -62.0 -18.61 61.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.271 0.557 . . . . 1.0 110.258 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.454 ' C ' ' H ' ' A' ' 8' ' ' LEU . 3.9 mp -79.6 138.04 20.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.105 -0.952 . . . . 1.0 108.995 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -77.44 23.73 0.21 Allowed 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.865 -0.42 . . . . 1.0 109.865 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.511 ' C ' HD12 ' A' ' 8' ' ' LEU . 2.5 pp -54.39 167.97 0.51 Allowed Pre-proline 0 N--CA 1.445 -0.698 0 CA-C-N 116.279 -0.419 . . . . 1.0 111.335 -179.288 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.462 ' CD ' ' H ' ' A' ' 10' ' ' LYS . 89.2 Cg_endo -92.42 -49.09 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.359 0 C-N-CA 122.271 1.981 . . . . 1.0 108.663 178.468 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LYS . . . . . 0.462 ' H ' ' CD ' ' A' ' 9' ' ' PRO . 59.1 pttt -173.4 32.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 114.649 -1.159 . . . . 1.0 108.313 177.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -49.79 -73.44 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 115.228 -0.896 . . . . 1.0 111.381 -178.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.519 ' O ' HG12 ' A' ' 16' ' ' VAL . 96.4 mt -63.31 -38.42 91.1 Favored 'General case' 0 C--O 1.211 -0.934 0 N-CA-C 108.639 -0.874 . . . . 1.0 108.639 178.841 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.15 -51.9 28.98 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.031 -0.532 . . . . 1.0 113.149 -177.655 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -79.54 -37.66 23.07 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.654 -0.578 . . . . 1.0 111.654 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.6 mt -76.2 -56.39 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 112.199 0.444 . . . . 1.0 112.199 -178.175 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.519 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.8 OUTLIER -54.91 -31.63 25.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 120.763 -0.375 . . . . 1.0 111.059 -176.911 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.1 mmt180 -66.5 -35.19 79.64 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 108.318 -0.993 . . . . 1.0 108.318 177.73 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.05 -39.44 94.08 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.661 -0.7 . . . . 1.0 109.43 178.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.8 mmt -60.33 -48.11 83.14 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.557 -0.747 . . . . 1.0 109.559 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.51 -42.06 87.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 114.682 -1.145 . . . . 1.0 109.7 179.258 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.8 -23.2 63.04 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.57 -1.012 . . . . 1.0 110.57 179.598 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.8 m -90.27 -27.32 19.54 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 121.145 0.498 . . . . 1.0 109.662 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -69.88 -49.59 50.79 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 115.456 -0.793 . . . . 1.0 110.235 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 . . . . . 0 CA--C 1.536 0.405 0 CA-C-N 115.101 -0.954 . . . . 1.0 112.181 179.122 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 42.3 p90 . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.987 0.422 . . . . 1.0 110.251 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 68.8 p -129.32 -6.12 4.81 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-O 122.066 0.936 . . . . 1.0 108.873 178.708 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.444 ' C ' ' H ' ' A' ' 8' ' ' LEU . 5.6 mt -76.51 145.84 9.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 113.68 -1.6 . . . . 1.0 108.821 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 62.3 mttp -78.47 23.81 0.29 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 109.855 -0.424 . . . . 1.0 109.855 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.462 ' O ' HD12 ' A' ' 8' ' ' LEU . 2.0 pp -55.06 169.09 0.45 Allowed Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 122.921 0.489 . . . . 1.0 111.813 -178.503 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -106.26 65.29 0.02 OUTLIER 'Trans proline' 0 N--CA 1.487 1.145 0 C-N-CA 123.576 2.85 . . . . 1.0 110.429 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 99.6 mttt 55.14 54.05 9.34 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 116.335 -0.393 . . . . 1.0 110.465 -178.289 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PHE . . . . . 0.403 ' H ' HD13 ' A' ' 8' ' ' LEU . 12.6 t80 -56.01 -76.63 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.246 0.546 . . . . 1.0 110.372 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.479 ' O ' HG12 ' A' ' 16' ' ' VAL . 95.7 mt -66.67 -37.37 84.63 Favored 'General case' 0 C--O 1.21 -1.003 0 CA-C-N 115.323 -0.853 . . . . 1.0 108.939 179.16 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.36 -44.54 44.81 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 121.358 -0.448 . . . . 1.0 112.687 -178.604 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.65 -43.0 8.02 Favored Glycine 0 CA--C 1.53 0.996 0 N-CA-C 111.521 -0.631 . . . . 1.0 111.521 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.6 mt -73.88 -53.59 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 N-CA-C 112.284 0.476 . . . . 1.0 112.284 -178.095 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.479 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.5 OUTLIER -57.89 -30.46 38.26 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.665 0 N-CA-C 109.925 -0.398 . . . . 1.0 109.925 -177.374 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 26.3 tpt180 -62.43 -39.31 92.92 Favored 'General case' 0 CA--C 1.518 -0.273 0 N-CA-C 108.595 -0.891 . . . . 1.0 108.595 177.822 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.99 -40.08 94.4 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 115.471 -0.786 . . . . 1.0 109.418 179.069 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 21.9 mmt -61.59 -44.09 97.65 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.53 -0.759 . . . . 1.0 110.361 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.1 mt -65.33 -42.79 92.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.423 -0.808 . . . . 1.0 111.174 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.38 -29.76 72.39 Favored Glycine 0 N--CA 1.462 0.419 0 N-CA-C 110.143 -1.183 . . . . 1.0 110.143 179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.5 m -78.06 -49.19 14.44 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 121.518 0.675 . . . . 1.0 109.4 178.772 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -64.32 -73.02 0.13 Allowed 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 114.864 -1.062 . . . . 1.0 110.811 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 45.4 ptt85 . . . . . 0 N--CA 1.483 1.178 0 C-N-CA 123.788 0.835 . . . . 1.0 112.867 -179.901 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.473 0.69 0 N-CA-C 111.752 0.279 . . . . 1.0 111.752 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 24.9 p 66.32 14.83 9.87 Favored 'General case' 0 N--CA 1.466 0.347 0 O-C-N 123.818 0.699 . . . . 1.0 110.991 -178.561 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.43 ' C ' ' H ' ' A' ' 8' ' ' LEU . 22.7 mt -121.96 138.39 52.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 108.115 -1.068 . . . . 1.0 108.115 179.542 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -75.32 23.0 0.11 Allowed 'General case' 0 N--CA 1.469 0.501 0 O-C-N 122.41 -0.181 . . . . 1.0 110.962 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.537 HD13 ' H ' ' A' ' 11' ' ' PHE . 2.8 pp -58.31 167.65 1.59 Allowed Pre-proline 0 CA--C 1.545 0.758 0 C-N-CA 122.309 0.244 . . . . 1.0 111.24 -179.458 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_endo -106.37 67.02 0.02 OUTLIER 'Trans proline' 0 N--CA 1.49 1.32 0 C-N-CA 123.648 2.898 . . . . 1.0 110.774 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 68.1 mttm 54.36 54.83 8.87 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 121.068 0.461 . . . . 1.0 110.188 -178.444 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PHE . . . . . 0.537 ' H ' HD13 ' A' ' 8' ' ' LEU . 9.4 t80 -54.33 -83.4 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 115.869 -0.605 . . . . 1.0 110.889 -179.071 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.523 ' O ' HG12 ' A' ' 16' ' ' VAL . 94.7 mt -60.79 -33.61 73.24 Favored 'General case' 0 C--O 1.214 -0.787 0 N-CA-C 109.111 -0.7 . . . . 1.0 109.111 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.36 -43.14 43.45 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.601 -0.599 . . . . 1.0 111.601 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -84.4 -48.96 4.84 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 112.067 -0.413 . . . . 1.0 112.067 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 3.5 mp -70.28 -46.6 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 112.645 0.609 . . . . 1.0 112.645 -177.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.523 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.4 p -56.82 -30.98 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 C-N-CA 120.042 -0.663 . . . . 1.0 111.005 -176.634 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -65.96 -36.1 82.39 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.315 -0.994 . . . . 1.0 108.315 177.692 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.28 -39.56 94.93 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.677 -0.692 . . . . 1.0 109.601 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 9.3 mmt -60.38 -48.54 81.32 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 115.759 -0.655 . . . . 1.0 109.91 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 98.1 mt -66.17 -42.67 88.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.731 -1.122 . . . . 1.0 110.268 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.32 -26.22 65.88 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.358 -1.097 . . . . 1.0 110.358 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -88.0 -39.43 14.69 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.257 0.551 . . . . 1.0 110.416 179.663 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -64.6 -48.26 75.58 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.347 -0.842 . . . . 1.0 111.504 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 39.7 mtm180 . . . . . 0 CA--C 1.539 0.543 0 CA-C-N 115.71 -0.677 . . . . 1.0 112.034 -179.875 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 27.4 m-85 . . . . . 0 N--CA 1.472 0.639 0 N-CA-C 110.189 -0.301 . . . . 1.0 110.189 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.3 p 57.37 20.55 6.02 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 115.476 -0.783 . . . . 1.0 111.046 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 28.0 mt -124.12 134.45 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 CA-C-N 114.548 -1.205 . . . . 1.0 107.754 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -76.41 38.85 0.19 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.753 0.311 . . . . 1.0 110.719 -178.86 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.502 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.4 OUTLIER -70.58 169.0 15.61 Favored Pre-proline 0 CA--C 1.548 0.893 0 CA-C-N 116.522 -0.308 . . . . 1.0 111.765 -178.747 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -106.81 56.88 0.01 OUTLIER 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 123.847 3.031 . . . . 1.0 108.038 176.453 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 62.9 mttp 62.96 48.12 4.04 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 114.662 -1.154 . . . . 1.0 110.268 -177.155 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -64.51 -70.12 0.24 Allowed 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.276 0.56 . . . . 1.0 110.271 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.55 ' O ' HG12 ' A' ' 16' ' ' VAL . 86.7 mt -62.36 -33.69 75.21 Favored 'General case' 0 C--O 1.212 -0.883 0 CA-C-N 115.41 -0.814 . . . . 1.0 109.131 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -48.88 -53.5 17.77 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 121.281 -0.485 . . . . 1.0 113.193 -177.433 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.56 -40.28 11.2 Favored Glycine 0 N--CA 1.47 0.964 0 CA-C-N 117.529 0.665 . . . . 1.0 111.758 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.406 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 95.8 mt -71.12 -51.27 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 N-CA-C 112.363 0.505 . . . . 1.0 112.363 -177.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.55 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.6 p -56.33 -30.56 30.74 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.538 0 C-N-CA 120.331 -0.548 . . . . 1.0 110.655 -177.484 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 18.8 mmm180 -65.23 -36.67 84.86 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.377 -0.971 . . . . 1.0 108.377 177.814 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.406 ' HB3' ' O ' ' A' ' 15' ' ' ILE . . . -63.78 -39.19 93.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.257 -0.883 . . . . 1.0 109.635 179.069 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.9 mmt -60.8 -45.8 93.01 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.639 -0.71 . . . . 1.0 109.867 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.9 mt -65.23 -42.2 93.62 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 114.802 -1.09 . . . . 1.0 110.533 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.4 -31.68 70.74 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 109.971 -1.252 . . . . 1.0 109.971 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.5 t -73.1 -37.31 66.78 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.487 0.66 . . . . 1.0 109.715 178.67 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -59.4 -48.59 81.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 114.746 -1.116 . . . . 1.0 111.421 -178.097 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 10.3 ptp85 . . . . . 0 N--CA 1.471 0.623 0 CA-C-O 120.839 0.352 . . . . 1.0 110.475 179.756 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 41.8 p90 . . . . . 0 N--CA 1.467 0.381 0 CA-C-O 121.068 0.461 . . . . 1.0 110.469 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 81.3 p -129.0 11.97 6.1 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.325 -0.852 . . . . 1.0 108.77 178.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.446 ' C ' ' H ' ' A' ' 8' ' ' LEU . 7.4 mt -102.18 142.93 15.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.208 -1.36 . . . . 1.0 108.969 -178.749 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -66.68 11.32 0.1 Allowed 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 111.937 0.347 . . . . 1.0 111.937 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.547 ' C ' HD12 ' A' ' 8' ' ' LEU . 3.6 pp -58.01 169.93 0.8 Allowed Pre-proline 0 CA--C 1.538 0.503 0 CA-C-O 119.539 -0.267 . . . . 1.0 111.221 -179.145 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.404 ' CG ' ' H ' ' A' ' 10' ' ' LYS . 83.9 Cg_endo -96.73 -63.12 0.01 OUTLIER 'Trans proline' 0 N--CA 1.489 1.224 0 C-N-CA 122.752 2.301 . . . . 1.0 109.17 178.378 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LYS . . . . . 0.404 ' H ' ' CG ' ' A' ' 9' ' ' PRO . 54.2 mtmt -157.75 36.68 0.26 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 107.908 -1.145 . . . . 1.0 107.908 178.214 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 23.0 t80 -48.44 -75.14 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.561 -0.745 . . . . 1.0 111.464 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.474 ' O ' HG12 ' A' ' 16' ' ' VAL . 90.9 mt -65.0 -38.93 92.57 Favored 'General case' 0 C--O 1.211 -0.943 0 N-CA-C 108.803 -0.814 . . . . 1.0 108.803 179.178 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.42 -50.95 33.72 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 121.313 -0.47 . . . . 1.0 112.874 -178.048 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.71 -38.81 26.74 Favored Glycine 0 CA--C 1.529 0.942 0 N-CA-C 111.685 -0.566 . . . . 1.0 111.685 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.78 -57.33 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 122.571 0.349 . . . . 1.0 111.895 -178.214 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.474 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.5 OUTLIER -55.13 -30.45 24.18 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 C-N-CA 120.962 -0.295 . . . . 1.0 110.542 -177.274 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 25.0 tpt180 -64.68 -39.45 93.69 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 108.466 -0.939 . . . . 1.0 108.466 177.866 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.21 -39.76 93.85 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.112 -0.949 . . . . 1.0 109.741 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.4 mmt -60.43 -47.76 84.7 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.667 -0.697 . . . . 1.0 109.669 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.4 mt -66.02 -42.18 89.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.669 -1.151 . . . . 1.0 110.027 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -60.99 -25.85 64.78 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.413 -1.075 . . . . 1.0 110.413 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.4 m -87.87 -35.3 17.83 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.253 0.549 . . . . 1.0 110.093 179.446 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -66.58 -49.07 67.59 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.361 -0.836 . . . . 1.0 111.378 -178.712 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.7 mtp85 . . . . . 0 CA--C 1.537 0.445 0 CA-C-N 115.839 -0.619 . . . . 1.0 111.594 -179.944 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 75.5 m-85 . . . . . 0 N--CA 1.465 0.32 0 N-CA-C 109.7 -0.481 . . . . 1.0 109.7 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.1 p -65.12 -10.0 27.28 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.56 -0.746 . . . . 1.0 110.087 -179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.444 ' C ' ' H ' ' A' ' 8' ' ' LEU . 3.8 mp -98.1 138.73 21.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 114.924 -1.034 . . . . 1.0 109.665 -179.331 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 61.0 pttt -67.52 9.16 0.27 Allowed 'General case' 0 CA--C 1.535 0.366 0 CA-C-N 116.352 -0.385 . . . . 1.0 111.18 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.549 ' C ' HD12 ' A' ' 8' ' ' LEU . 3.1 pp -48.61 165.48 0.25 Allowed Pre-proline 0 CA--C 1.543 0.704 0 N-CA-C 112.349 0.5 . . . . 1.0 112.349 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.482 ' CD ' ' H ' ' A' ' 10' ' ' LYS . 49.7 Cg_endo -95.39 -51.41 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.364 0 C-N-CA 122.97 2.447 . . . . 1.0 109.393 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LYS . . . . . 0.482 ' H ' ' CD ' ' A' ' 9' ' ' PRO . 60.3 pttt -167.58 32.01 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 114.972 -1.013 . . . . 1.0 108.64 178.533 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 40.6 t80 -55.66 -73.12 0.06 Allowed 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.185 -0.916 . . . . 1.0 111.357 -178.901 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.514 ' O ' HG12 ' A' ' 16' ' ' VAL . 92.9 mt -63.29 -38.85 92.76 Favored 'General case' 0 C--O 1.211 -0.932 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 179.288 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.12 -52.62 26.3 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 121.243 -0.503 . . . . 1.0 112.818 -177.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.09 -39.34 27.66 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.686 -0.566 . . . . 1.0 111.686 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.417 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 95.6 mt -76.01 -56.85 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 112.357 0.503 . . . . 1.0 112.357 -178.218 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.514 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.8 OUTLIER -53.99 -31.4 21.06 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.464 0 CA-C-O 121.148 0.499 . . . . 1.0 110.889 -177.279 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 59.8 ttt85 -67.33 -36.62 81.82 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 108.392 -0.966 . . . . 1.0 108.392 178.572 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.417 ' HB3' ' O ' ' A' ' 15' ' ' ILE . . . -63.22 -39.52 94.86 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.046 -0.979 . . . . 1.0 109.466 179.08 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 9.8 mmt -60.11 -48.58 81.11 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.646 0.736 . . . . 1.0 109.568 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.0 mt -66.41 -41.66 88.97 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.411 -1.268 . . . . 1.0 109.795 179.372 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -74.21 -5.32 71.16 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.437 -0.801 . . . . 1.0 111.948 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 38.6 t -93.59 -30.94 14.72 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 121.716 0.769 . . . . 1.0 108.957 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.95 -45.78 33.22 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 114.27 -1.332 . . . . 1.0 108.751 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 85.8 mtt-85 . . . . . 0 CA--C 1.535 0.377 0 CA-C-N 114.971 -1.013 . . . . 1.0 112.193 179.65 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 34.3 p90 . . . . . 0 CA--C 1.528 0.126 0 CA-C-O 121.053 0.454 . . . . 1.0 110.833 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 70.6 p -127.03 20.99 6.88 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.802 0.81 . . . . 1.0 109.586 179.527 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.428 ' C ' ' H ' ' A' ' 8' ' ' LEU . 34.1 mt -113.35 147.65 16.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 114.241 -1.345 . . . . 1.0 109.079 -178.584 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -76.11 21.02 0.18 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-O 120.753 0.311 . . . . 1.0 110.77 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.52 HD13 ' H ' ' A' ' 11' ' ' PHE . 2.6 pp -59.39 167.25 2.4 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-N 116.302 -0.408 . . . . 1.0 111.503 -179.079 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -105.0 64.73 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 123.532 2.822 . . . . 1.0 110.913 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 97.6 mttt 54.95 55.81 7.33 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.274 0.559 . . . . 1.0 109.733 -178.464 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PHE . . . . . 0.52 ' H ' HD13 ' A' ' 8' ' ' LEU . 12.5 t80 -53.53 -78.79 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.471 -0.786 . . . . 1.0 111.091 -178.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.463 ' O ' HG12 ' A' ' 16' ' ' VAL . 85.8 mt -65.31 -38.13 89.23 Favored 'General case' 0 C--O 1.211 -0.938 0 N-CA-C 108.357 -0.979 . . . . 1.0 108.357 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.21 -52.67 22.1 Favored Glycine 0 CA--C 1.532 1.12 0 CA-C-N 115.95 -0.568 . . . . 1.0 112.61 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.85 -39.02 25.66 Favored Glycine 0 CA--C 1.531 1.046 0 CA-C-N 117.253 0.526 . . . . 1.0 112.037 179.854 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.6 mt -75.53 -55.76 10.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 112.042 0.386 . . . . 1.0 112.042 -178.322 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.463 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.4 OUTLIER -56.82 -30.0 31.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 120.741 0.305 . . . . 1.0 110.385 -177.202 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 32.7 tpt85 -65.35 -38.79 91.16 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.217 -1.031 . . . . 1.0 108.217 177.608 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.68 -39.05 92.75 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.273 -0.876 . . . . 1.0 109.592 179.113 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.6 mmt -60.36 -47.19 87.11 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.462 0.649 . . . . 1.0 109.359 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.8 mt -65.75 -41.6 91.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.806 -1.088 . . . . 1.0 109.584 178.842 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.35 -24.45 59.13 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.939 -0.865 . . . . 1.0 110.939 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.1 m -87.48 -35.28 18.32 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 121.285 0.564 . . . . 1.0 109.97 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -65.14 -48.53 73.22 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.09 -0.959 . . . . 1.0 111.677 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 42.5 mtm180 . . . . . 0 CA--C 1.537 0.471 0 CA-C-N 115.986 -0.552 . . . . 1.0 111.883 179.524 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.409 ' C ' ' H ' ' A' ' 6' ' ' ILE . 76.3 m-85 . . . . . 0 N--CA 1.464 0.273 0 CA-C-O 121.284 0.564 . . . . 1.0 110.599 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 29.8 p -63.5 -4.64 2.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.224 -0.898 . . . . 1.0 110.393 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.412 ' C ' ' H ' ' A' ' 8' ' ' LEU . 4.2 mp -103.5 137.62 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.125 -0.943 . . . . 1.0 109.299 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -79.24 31.37 0.22 Allowed 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 110.114 -0.328 . . . . 1.0 110.114 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.509 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.8 OUTLIER -52.95 167.64 0.39 Allowed Pre-proline 0 CA--C 1.549 0.904 0 CA-C-N 116.079 -0.509 . . . . 1.0 111.877 -178.612 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -102.55 5.92 0.44 Allowed 'Trans proline' 0 N--CA 1.487 1.117 0 C-N-CA 123.414 2.743 . . . . 1.0 110.206 179.086 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 25.1 mmtp 122.83 39.97 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 126.969 2.107 . . . . 1.0 107.886 -179.2 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -62.62 -69.15 0.28 Allowed 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.352 -0.84 . . . . 1.0 110.178 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.516 ' O ' HG12 ' A' ' 16' ' ' VAL . 89.6 mt -63.09 -34.88 78.56 Favored 'General case' 0 C--O 1.211 -0.951 0 N-CA-C 108.898 -0.779 . . . . 1.0 108.898 179.39 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.36 -52.6 22.97 Favored Glycine 0 CA--C 1.529 0.966 0 CA-C-N 116.116 -0.493 . . . . 1.0 113.13 -177.574 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -80.77 -39.94 13.07 Favored Glycine 0 CA--C 1.529 0.949 0 CA-C-N 117.491 0.645 . . . . 1.0 111.72 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.1 mt -72.48 -53.21 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 112.393 0.516 . . . . 1.0 112.393 -178.152 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.516 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.3 p -55.28 -30.98 25.87 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 C-N-CA 120.404 -0.518 . . . . 1.0 110.816 -177.274 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -66.53 -35.63 80.71 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 108.332 -0.988 . . . . 1.0 108.332 177.71 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.58 -39.36 94.19 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.577 -0.738 . . . . 1.0 109.459 178.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 10.4 mmt -60.18 -46.97 87.9 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.535 -0.757 . . . . 1.0 109.706 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.8 mt -66.27 -42.64 88.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.674 -1.148 . . . . 1.0 109.829 179.398 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.87 -24.27 64.44 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.43 -1.068 . . . . 1.0 110.43 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -88.83 -29.54 19.62 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.169 0.509 . . . . 1.0 109.855 179.415 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -66.35 -49.79 65.75 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 115.392 -0.822 . . . . 1.0 111.035 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 49.7 mtm-85 . . . . . 0 CA--C 1.535 0.394 0 CA-C-N 115.538 -0.755 . . . . 1.0 111.857 179.88 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 43.0 p90 . . . . . 0 N--CA 1.47 0.558 0 N-CA-C 109.858 -0.423 . . . . 1.0 109.858 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.2 t -135.62 -5.03 2.25 Favored 'General case' 0 N--CA 1.48 1.047 0 CA-C-O 121.972 0.892 . . . . 1.0 108.989 179.029 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.8 mt -68.29 -3.89 2.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 113.89 -1.505 . . . . 1.0 109.867 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 48.4 mttt 52.36 30.03 7.59 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 114.867 -1.06 . . . . 1.0 109.257 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.528 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.5 OUTLIER -61.63 169.14 2.67 Favored Pre-proline 0 N--CA 1.443 -0.82 0 CA-C-N 113.406 -1.725 . . . . 1.0 111.705 -178.05 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -105.4 63.58 0.02 OUTLIER 'Trans proline' 0 N--CA 1.482 0.821 0 C-N-CA 123.569 2.846 . . . . 1.0 108.898 176.77 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt 58.26 45.82 16.61 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 115.299 -0.864 . . . . 1.0 111.01 -178.284 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -64.32 -73.8 0.11 Allowed 'General case' 0 N--CA 1.472 0.669 0 CA-C-O 121.301 0.572 . . . . 1.0 109.688 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.472 ' O ' HG12 ' A' ' 16' ' ' VAL . 87.3 mt -64.14 -34.59 78.41 Favored 'General case' 0 C--O 1.214 -0.774 0 CA-C-N 115.291 -0.868 . . . . 1.0 109.141 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -48.49 -50.15 24.97 Favored Glycine 0 CA--C 1.528 0.897 0 CA-C-N 116.153 -0.476 . . . . 1.0 112.814 -177.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.22 -41.93 9.01 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 117.468 0.634 . . . . 1.0 112.072 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.41 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 91.2 mt -72.05 -49.73 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 112.845 0.683 . . . . 1.0 112.845 -177.8 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.472 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.4 p -55.38 -32.33 29.18 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.474 0 C-N-CA 120.45 -0.5 . . . . 1.0 111.1 -176.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 87.4 mtm180 -65.57 -35.2 80.15 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 108.31 -0.996 . . . . 1.0 108.31 177.555 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.41 ' HB3' ' O ' ' A' ' 15' ' ' ILE . . . -63.01 -39.13 93.82 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.525 -0.761 . . . . 1.0 109.304 179.24 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.6 mmt -60.77 -46.61 89.8 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.646 -0.706 . . . . 1.0 109.759 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.3 mt -65.52 -41.91 92.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 114.591 -1.186 . . . . 1.0 110.313 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.62 -27.92 61.96 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 110.401 -1.08 . . . . 1.0 110.401 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.2 t -73.24 -35.61 66.28 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.896 0.855 . . . . 1.0 109.257 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -61.07 -40.3 93.15 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.225 -1.352 . . . . 1.0 110.969 -178.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 24.0 mmm180 . . . . . 0 N--CA 1.469 0.486 0 CA-C-N 116.214 -0.448 . . . . 1.0 110.627 -178.755 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 36.3 p90 . . . . . 0 C--O 1.222 -0.382 0 CA-C-O 119.899 -0.096 . . . . 1.0 110.988 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.1 t 44.32 42.77 5.52 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 114.265 1.209 . . . . 1.0 114.265 178.058 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.412 HG22 ' H ' ' A' ' 8' ' ' LEU . 29.6 mt -133.78 144.49 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.781 -1.192 . . . . 1.0 107.781 179.22 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -72.84 17.48 0.12 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.063 0.394 . . . . 1.0 112.063 -178.475 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.586 HD13 ' H ' ' A' ' 11' ' ' PHE . 2.7 pp -62.08 168.84 3.32 Favored Pre-proline 0 CA--C 1.543 0.707 0 C-N-CA 122.862 0.465 . . . . 1.0 110.648 -179.679 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -104.21 64.1 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.373 0 C-N-CA 123.475 2.784 . . . . 1.0 111.802 -179.147 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 16.1 ttmm 58.31 54.91 5.35 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-O 121.174 0.511 . . . . 1.0 110.481 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PHE . . . . . 0.586 ' H ' HD13 ' A' ' 8' ' ' LEU . 9.0 t80 -59.93 -79.04 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 115.54 -0.754 . . . . 1.0 110.96 -179.112 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.485 ' O ' HG12 ' A' ' 16' ' ' VAL . 86.0 mt -65.1 -37.74 88.44 Favored 'General case' 0 C--O 1.212 -0.868 0 CA-C-N 115.576 -0.738 . . . . 1.0 109.015 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.85 -45.85 40.33 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-N 115.997 -0.547 . . . . 1.0 112.688 -178.137 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.45 -41.34 9.19 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 111.607 -0.597 . . . . 1.0 111.607 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.4 mt -74.07 -54.85 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 112.121 0.415 . . . . 1.0 112.121 -178.161 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.485 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.7 OUTLIER -56.65 -31.3 34.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.102 0.477 . . . . 1.0 110.703 -177.114 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -65.52 -37.05 85.62 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.66 -0.867 . . . . 1.0 108.66 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.84 -40.07 96.33 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.022 -0.99 . . . . 1.0 109.24 178.475 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.1 mmt -60.57 -47.26 86.99 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.519 -0.764 . . . . 1.0 109.81 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.0 mt -65.84 -40.57 91.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 114.68 -1.145 . . . . 1.0 109.989 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.24 -26.92 59.64 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.726 -0.949 . . . . 1.0 110.726 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.9 m -87.42 -43.2 12.26 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 121.193 0.52 . . . . 1.0 110.344 179.385 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -66.75 -49.11 67.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.407 -0.815 . . . . 1.0 111.19 -178.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 52.9 mtp180 . . . . . 0 CA--C 1.535 0.395 0 CA-C-N 115.315 -0.857 . . . . 1.0 111.917 179.726 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.5 ttt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 108.931 -0.766 . . . . 1.0 108.931 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -62.61 -44.73 95.55 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.073 -0.512 . . . . 1.0 109.964 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.409 ' CD2' ' O ' ' A' ' 4' ' ' TYR . 75.6 t80 -164.3 153.0 13.12 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.028 -0.533 . . . . 1.0 109.66 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.409 ' O ' ' CD2' ' A' ' 3' ' ' PHE . 90.0 m-85 -75.44 127.43 33.11 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.929 0.395 . . . . 1.0 110.524 -179.698 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.3 t -62.0 -18.61 61.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.271 0.557 . . . . 1.0 110.258 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.454 ' C ' ' H ' ' A' ' 8' ' ' LEU . 3.9 mp -79.6 138.04 20.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.105 -0.952 . . . . 1.0 108.995 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -77.44 23.73 0.21 Allowed 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.865 -0.42 . . . . 1.0 109.865 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.511 ' C ' HD12 ' A' ' 8' ' ' LEU . 2.5 pp -54.39 167.97 0.51 Allowed Pre-proline 0 N--CA 1.445 -0.698 0 CA-C-N 116.279 -0.419 . . . . 1.0 111.335 -179.288 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.462 ' CD ' ' H ' ' A' ' 10' ' ' LYS . 89.2 Cg_endo -92.42 -49.09 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.359 0 C-N-CA 122.271 1.981 . . . . 1.0 108.663 178.468 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LYS . . . . . 0.462 ' H ' ' CD ' ' A' ' 9' ' ' PRO . 59.1 pttt -173.4 32.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 114.649 -1.159 . . . . 1.0 108.313 177.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -49.79 -73.44 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 115.228 -0.896 . . . . 1.0 111.381 -178.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.519 ' O ' HG12 ' A' ' 16' ' ' VAL . 96.4 mt -63.31 -38.42 91.1 Favored 'General case' 0 C--O 1.211 -0.934 0 N-CA-C 108.639 -0.874 . . . . 1.0 108.639 178.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.15 -51.9 28.98 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.031 -0.532 . . . . 1.0 113.149 -177.655 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -79.54 -37.66 23.07 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.654 -0.578 . . . . 1.0 111.654 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.6 mt -76.2 -56.39 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 112.199 0.444 . . . . 1.0 112.199 -178.175 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.519 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.8 OUTLIER -54.91 -31.63 25.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 120.763 -0.375 . . . . 1.0 111.059 -176.911 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.1 mmt180 -66.5 -35.19 79.64 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 108.318 -0.993 . . . . 1.0 108.318 177.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.05 -39.44 94.08 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.661 -0.7 . . . . 1.0 109.43 178.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.8 mmt -60.33 -48.11 83.14 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.557 -0.747 . . . . 1.0 109.559 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.51 -42.06 87.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 114.682 -1.145 . . . . 1.0 109.7 179.258 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.8 -23.2 63.04 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.57 -1.012 . . . . 1.0 110.57 179.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.8 m -90.27 -27.32 19.54 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 121.145 0.498 . . . . 1.0 109.662 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -69.88 -49.59 50.79 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 115.456 -0.793 . . . . 1.0 110.235 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 46.94 79.49 0.06 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.101 -0.954 . . . . 1.0 112.181 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 64.7 tttp -62.34 -44.79 95.65 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.303 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 50.5 p-10 . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.816 -1.088 . . . . 1.0 110.284 179.868 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.1 ptt? . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 108.906 -0.775 . . . . 1.0 108.906 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -166.05 131.03 2.32 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.669 -0.493 . . . . 1.0 109.669 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -79.15 -174.2 3.99 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.299 0.571 . . . . 1.0 110.981 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 42.3 p90 -154.08 159.48 41.54 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.406 -0.815 . . . . 1.0 110.251 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 68.8 p -129.32 -6.12 4.81 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-O 122.066 0.936 . . . . 1.0 108.873 178.708 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.444 ' C ' ' H ' ' A' ' 8' ' ' LEU . 5.6 mt -76.51 145.84 9.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 113.68 -1.6 . . . . 1.0 108.821 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 62.3 mttp -78.47 23.81 0.29 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 109.855 -0.424 . . . . 1.0 109.855 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.462 ' O ' HD12 ' A' ' 8' ' ' LEU . 2.0 pp -55.06 169.09 0.45 Allowed Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 122.921 0.489 . . . . 1.0 111.813 -178.503 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -106.26 65.29 0.02 OUTLIER 'Trans proline' 0 N--CA 1.487 1.145 0 C-N-CA 123.576 2.85 . . . . 1.0 110.429 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 99.6 mttt 55.14 54.05 9.34 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 116.335 -0.393 . . . . 1.0 110.465 -178.289 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PHE . . . . . 0.403 ' H ' HD13 ' A' ' 8' ' ' LEU . 12.6 t80 -56.01 -76.63 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.246 0.546 . . . . 1.0 110.372 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.479 ' O ' HG12 ' A' ' 16' ' ' VAL . 95.7 mt -66.67 -37.37 84.63 Favored 'General case' 0 C--O 1.21 -1.003 0 CA-C-N 115.323 -0.853 . . . . 1.0 108.939 179.16 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.36 -44.54 44.81 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 121.358 -0.448 . . . . 1.0 112.687 -178.604 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.65 -43.0 8.02 Favored Glycine 0 CA--C 1.53 0.996 0 N-CA-C 111.521 -0.631 . . . . 1.0 111.521 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.6 mt -73.88 -53.59 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 N-CA-C 112.284 0.476 . . . . 1.0 112.284 -178.095 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.479 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.5 OUTLIER -57.89 -30.46 38.26 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.665 0 N-CA-C 109.925 -0.398 . . . . 1.0 109.925 -177.374 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 26.3 tpt180 -62.43 -39.31 92.92 Favored 'General case' 0 CA--C 1.518 -0.273 0 N-CA-C 108.595 -0.891 . . . . 1.0 108.595 177.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.99 -40.08 94.4 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 115.471 -0.786 . . . . 1.0 109.418 179.069 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 21.9 mmt -61.59 -44.09 97.65 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.53 -0.759 . . . . 1.0 110.361 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.1 mt -65.33 -42.79 92.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.423 -0.808 . . . . 1.0 111.174 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.38 -29.76 72.39 Favored Glycine 0 N--CA 1.462 0.419 0 N-CA-C 110.143 -1.183 . . . . 1.0 110.143 179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.5 m -78.06 -49.19 14.44 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 121.518 0.675 . . . . 1.0 109.4 178.772 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -64.32 -73.02 0.13 Allowed 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 114.864 -1.062 . . . . 1.0 110.811 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 45.4 ptt85 29.05 46.9 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.788 0.835 . . . . 1.0 112.867 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -62.98 135.19 57.16 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.716 -0.674 . . . . 1.0 110.303 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 53.3 p-10 . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.199 -0.905 . . . . 1.0 110.964 -179.968 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.0 mtt . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 108.978 -0.749 . . . . 1.0 108.978 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -66.58 121.01 14.4 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 109.604 -0.517 . . . . 1.0 109.604 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 52.8 t80 -64.7 -49.77 69.6 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 121.196 0.522 . . . . 1.0 110.412 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -72.26 -38.04 68.96 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 115.381 -0.827 . . . . 1.0 111.752 -179.271 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 24.9 p 66.32 14.83 9.87 Favored 'General case' 0 N--CA 1.466 0.347 0 O-C-N 123.818 0.699 . . . . 1.0 110.991 -178.561 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.43 ' C ' ' H ' ' A' ' 8' ' ' LEU . 22.7 mt -121.96 138.39 52.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 108.115 -1.068 . . . . 1.0 108.115 179.542 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -75.32 23.0 0.11 Allowed 'General case' 0 N--CA 1.469 0.501 0 O-C-N 122.41 -0.181 . . . . 1.0 110.962 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.537 HD13 ' H ' ' A' ' 11' ' ' PHE . 2.8 pp -58.31 167.65 1.59 Allowed Pre-proline 0 CA--C 1.545 0.758 0 C-N-CA 122.309 0.244 . . . . 1.0 111.24 -179.458 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_endo -106.37 67.02 0.02 OUTLIER 'Trans proline' 0 N--CA 1.49 1.32 0 C-N-CA 123.648 2.898 . . . . 1.0 110.774 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 68.1 mttm 54.36 54.83 8.87 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 121.068 0.461 . . . . 1.0 110.188 -178.444 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PHE . . . . . 0.537 ' H ' HD13 ' A' ' 8' ' ' LEU . 9.4 t80 -54.33 -83.4 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 115.869 -0.605 . . . . 1.0 110.889 -179.071 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.523 ' O ' HG12 ' A' ' 16' ' ' VAL . 94.7 mt -60.79 -33.61 73.24 Favored 'General case' 0 C--O 1.214 -0.787 0 N-CA-C 109.111 -0.7 . . . . 1.0 109.111 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.36 -43.14 43.45 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.601 -0.599 . . . . 1.0 111.601 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -84.4 -48.96 4.84 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 112.067 -0.413 . . . . 1.0 112.067 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 3.5 mp -70.28 -46.6 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 112.645 0.609 . . . . 1.0 112.645 -177.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.523 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.4 p -56.82 -30.98 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 C-N-CA 120.042 -0.663 . . . . 1.0 111.005 -176.634 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -65.96 -36.1 82.39 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.315 -0.994 . . . . 1.0 108.315 177.692 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.28 -39.56 94.93 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.677 -0.692 . . . . 1.0 109.601 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 9.3 mmt -60.38 -48.54 81.32 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 115.759 -0.655 . . . . 1.0 109.91 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 98.1 mt -66.17 -42.67 88.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.731 -1.122 . . . . 1.0 110.268 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.32 -26.22 65.88 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.358 -1.097 . . . . 1.0 110.358 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -88.0 -39.43 14.69 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.257 0.551 . . . . 1.0 110.416 179.663 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -64.6 -48.26 75.58 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.347 -0.842 . . . . 1.0 111.504 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 39.7 mtm180 42.33 -163.65 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.71 -0.677 . . . . 1.0 112.034 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp 55.33 -169.04 0.08 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.228 -0.442 . . . . 1.0 110.708 -179.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 117.97 -1.014 . . . . 1.0 110.408 -179.928 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.1 ttt . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.044 -0.725 . . . . 1.0 109.044 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 62.5 tttp 56.97 90.22 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.124 -0.489 . . . . 1.0 110.79 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.434 ' CD2' ' O ' ' A' ' 3' ' ' PHE . 31.3 p90 -70.51 105.6 3.15 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 116.117 -0.492 . . . . 1.0 110.377 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 27.4 m-85 -73.01 -52.14 15.55 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 116.484 -0.325 . . . . 1.0 110.189 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.3 p 57.37 20.55 6.02 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 115.476 -0.783 . . . . 1.0 111.046 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 28.0 mt -124.12 134.45 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 CA-C-N 114.548 -1.205 . . . . 1.0 107.754 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -76.41 38.85 0.19 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.753 0.311 . . . . 1.0 110.719 -178.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.502 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.4 OUTLIER -70.58 169.0 15.61 Favored Pre-proline 0 CA--C 1.548 0.893 0 CA-C-N 116.522 -0.308 . . . . 1.0 111.765 -178.747 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -106.81 56.88 0.01 OUTLIER 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 123.847 3.031 . . . . 1.0 108.038 176.453 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 62.9 mttp 62.96 48.12 4.04 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 114.662 -1.154 . . . . 1.0 110.268 -177.155 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -64.51 -70.12 0.24 Allowed 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.276 0.56 . . . . 1.0 110.271 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.55 ' O ' HG12 ' A' ' 16' ' ' VAL . 86.7 mt -62.36 -33.69 75.21 Favored 'General case' 0 C--O 1.212 -0.883 0 CA-C-N 115.41 -0.814 . . . . 1.0 109.131 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -48.88 -53.5 17.77 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 121.281 -0.485 . . . . 1.0 113.193 -177.433 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.56 -40.28 11.2 Favored Glycine 0 N--CA 1.47 0.964 0 CA-C-N 117.529 0.665 . . . . 1.0 111.758 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.406 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 95.8 mt -71.12 -51.27 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 N-CA-C 112.363 0.505 . . . . 1.0 112.363 -177.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.55 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.6 p -56.33 -30.56 30.74 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.538 0 C-N-CA 120.331 -0.548 . . . . 1.0 110.655 -177.484 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 18.8 mmm180 -65.23 -36.67 84.86 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.377 -0.971 . . . . 1.0 108.377 177.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.406 ' HB3' ' O ' ' A' ' 15' ' ' ILE . . . -63.78 -39.19 93.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.257 -0.883 . . . . 1.0 109.635 179.069 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.9 mmt -60.8 -45.8 93.01 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.639 -0.71 . . . . 1.0 109.867 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.9 mt -65.23 -42.2 93.62 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 114.802 -1.09 . . . . 1.0 110.533 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.4 -31.68 70.74 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 109.971 -1.252 . . . . 1.0 109.971 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.5 t -73.1 -37.31 66.78 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.487 0.66 . . . . 1.0 109.715 178.67 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -59.4 -48.59 81.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 114.746 -1.116 . . . . 1.0 111.421 -178.097 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 10.3 ptp85 -80.63 160.21 25.14 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 120.839 0.352 . . . . 1.0 110.475 179.756 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? -61.65 -48.32 81.37 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.927 -0.768 . . . . 1.0 108.927 -179.652 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.6 t70 . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 117.994 -1.003 . . . . 1.0 110.092 179.295 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 81.6 mtp . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 108.921 -0.77 . . . . 1.0 108.921 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -62.71 -41.97 99.41 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.137 -0.483 . . . . 1.0 110.062 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -78.14 -176.34 4.54 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.053 -0.521 . . . . 1.0 110.311 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -158.21 161.48 37.8 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 115.756 -0.656 . . . . 1.0 110.469 178.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 81.3 p -129.0 11.97 6.1 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.325 -0.852 . . . . 1.0 108.77 178.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.446 ' C ' ' H ' ' A' ' 8' ' ' LEU . 7.4 mt -102.18 142.93 15.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.208 -1.36 . . . . 1.0 108.969 -178.749 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -66.68 11.32 0.1 Allowed 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 111.937 0.347 . . . . 1.0 111.937 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.547 ' C ' HD12 ' A' ' 8' ' ' LEU . 3.6 pp -58.01 169.93 0.8 Allowed Pre-proline 0 CA--C 1.538 0.503 0 CA-C-O 119.539 -0.267 . . . . 1.0 111.221 -179.145 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.404 ' CG ' ' H ' ' A' ' 10' ' ' LYS . 83.9 Cg_endo -96.73 -63.12 0.01 OUTLIER 'Trans proline' 0 N--CA 1.489 1.224 0 C-N-CA 122.752 2.301 . . . . 1.0 109.17 178.378 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LYS . . . . . 0.404 ' H ' ' CG ' ' A' ' 9' ' ' PRO . 54.2 mtmt -157.75 36.68 0.26 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 107.908 -1.145 . . . . 1.0 107.908 178.214 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 23.0 t80 -48.44 -75.14 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.561 -0.745 . . . . 1.0 111.464 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.474 ' O ' HG12 ' A' ' 16' ' ' VAL . 90.9 mt -65.0 -38.93 92.57 Favored 'General case' 0 C--O 1.211 -0.943 0 N-CA-C 108.803 -0.814 . . . . 1.0 108.803 179.178 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.42 -50.95 33.72 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 121.313 -0.47 . . . . 1.0 112.874 -178.048 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.71 -38.81 26.74 Favored Glycine 0 CA--C 1.529 0.942 0 N-CA-C 111.685 -0.566 . . . . 1.0 111.685 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.78 -57.33 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 122.571 0.349 . . . . 1.0 111.895 -178.214 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.474 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.5 OUTLIER -55.13 -30.45 24.18 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 C-N-CA 120.962 -0.295 . . . . 1.0 110.542 -177.274 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 25.0 tpt180 -64.68 -39.45 93.69 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 108.466 -0.939 . . . . 1.0 108.466 177.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.21 -39.76 93.85 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.112 -0.949 . . . . 1.0 109.741 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.4 mmt -60.43 -47.76 84.7 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.667 -0.697 . . . . 1.0 109.669 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.4 mt -66.02 -42.18 89.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.669 -1.151 . . . . 1.0 110.027 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -60.99 -25.85 64.78 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.413 -1.075 . . . . 1.0 110.413 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.4 m -87.87 -35.3 17.83 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.253 0.549 . . . . 1.0 110.093 179.446 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -66.58 -49.07 67.59 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.361 -0.836 . . . . 1.0 111.378 -178.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.7 mtp85 50.34 -161.64 0.06 Allowed 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.839 -0.619 . . . . 1.0 111.594 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 31.3 mtmm 53.58 91.63 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.08 -0.509 . . . . 1.0 111.08 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 51.9 p-10 . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 117.983 -1.008 . . . . 1.0 110.337 -179.986 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 72.8 mtp . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 108.888 -0.782 . . . . 1.0 108.888 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -65.38 -8.32 17.98 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.863 -0.608 . . . . 1.0 110.539 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -62.8 114.8 3.84 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-O 120.881 0.372 . . . . 1.0 110.264 -179.404 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 75.5 m-85 -85.89 140.0 30.76 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.981 -0.554 . . . . 1.0 109.7 178.617 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.1 p -65.12 -10.0 27.28 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.56 -0.746 . . . . 1.0 110.087 -179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.444 ' C ' ' H ' ' A' ' 8' ' ' LEU . 3.8 mp -98.1 138.73 21.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 114.924 -1.034 . . . . 1.0 109.665 -179.331 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 61.0 pttt -67.52 9.16 0.27 Allowed 'General case' 0 CA--C 1.535 0.366 0 CA-C-N 116.352 -0.385 . . . . 1.0 111.18 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.549 ' C ' HD12 ' A' ' 8' ' ' LEU . 3.1 pp -48.61 165.48 0.25 Allowed Pre-proline 0 CA--C 1.543 0.704 0 N-CA-C 112.349 0.5 . . . . 1.0 112.349 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.482 ' CD ' ' H ' ' A' ' 10' ' ' LYS . 49.7 Cg_endo -95.39 -51.41 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.364 0 C-N-CA 122.97 2.447 . . . . 1.0 109.393 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LYS . . . . . 0.482 ' H ' ' CD ' ' A' ' 9' ' ' PRO . 60.3 pttt -167.58 32.01 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 114.972 -1.013 . . . . 1.0 108.64 178.533 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 40.6 t80 -55.66 -73.12 0.06 Allowed 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.185 -0.916 . . . . 1.0 111.357 -178.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.514 ' O ' HG12 ' A' ' 16' ' ' VAL . 92.9 mt -63.29 -38.85 92.76 Favored 'General case' 0 C--O 1.211 -0.932 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 179.288 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.12 -52.62 26.3 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 121.243 -0.503 . . . . 1.0 112.818 -177.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.09 -39.34 27.66 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.686 -0.566 . . . . 1.0 111.686 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.417 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 95.6 mt -76.01 -56.85 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 112.357 0.503 . . . . 1.0 112.357 -178.218 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.514 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.8 OUTLIER -53.99 -31.4 21.06 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.464 0 CA-C-O 121.148 0.499 . . . . 1.0 110.889 -177.279 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 59.8 ttt85 -67.33 -36.62 81.82 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 108.392 -0.966 . . . . 1.0 108.392 178.572 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.417 ' HB3' ' O ' ' A' ' 15' ' ' ILE . . . -63.22 -39.52 94.86 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.046 -0.979 . . . . 1.0 109.466 179.08 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 9.8 mmt -60.11 -48.58 81.11 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.646 0.736 . . . . 1.0 109.568 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.0 mt -66.41 -41.66 88.97 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.411 -1.268 . . . . 1.0 109.795 179.372 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -74.21 -5.32 71.16 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.437 -0.801 . . . . 1.0 111.948 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 38.6 t -93.59 -30.94 14.72 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 121.716 0.769 . . . . 1.0 108.957 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.95 -45.78 33.22 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 114.27 -1.332 . . . . 1.0 108.751 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 85.8 mtt-85 48.34 17.0 0.11 Allowed 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 114.971 -1.013 . . . . 1.0 112.193 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -162.62 132.52 4.5 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.671 0.272 . . . . 1.0 110.442 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 61.3 t0 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.947 -1.025 . . . . 1.0 110.537 -179.776 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.2 mpt? . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 108.973 -0.751 . . . . 1.0 108.973 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -75.29 132.5 41.06 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.368 -0.378 . . . . 1.0 110.454 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.494 ' CD1' ' N ' ' A' ' 4' ' ' TYR . 46.3 p90 -143.32 -38.6 0.33 Allowed 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 120.899 0.381 . . . . 1.0 110.048 179.429 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.494 ' N ' ' CD1' ' A' ' 3' ' ' PHE . 34.3 p90 -62.7 166.14 5.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.02 -0.536 . . . . 1.0 110.833 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 70.6 p -127.03 20.99 6.88 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.802 0.81 . . . . 1.0 109.586 179.527 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.428 ' C ' ' H ' ' A' ' 8' ' ' LEU . 34.1 mt -113.35 147.65 16.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 114.241 -1.345 . . . . 1.0 109.079 -178.584 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -76.11 21.02 0.18 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-O 120.753 0.311 . . . . 1.0 110.77 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.52 HD13 ' H ' ' A' ' 11' ' ' PHE . 2.6 pp -59.39 167.25 2.4 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-N 116.302 -0.408 . . . . 1.0 111.503 -179.079 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -105.0 64.73 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 123.532 2.822 . . . . 1.0 110.913 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 97.6 mttt 54.95 55.81 7.33 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.274 0.559 . . . . 1.0 109.733 -178.464 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PHE . . . . . 0.52 ' H ' HD13 ' A' ' 8' ' ' LEU . 12.5 t80 -53.53 -78.79 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.471 -0.786 . . . . 1.0 111.091 -178.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.463 ' O ' HG12 ' A' ' 16' ' ' VAL . 85.8 mt -65.31 -38.13 89.23 Favored 'General case' 0 C--O 1.211 -0.938 0 N-CA-C 108.357 -0.979 . . . . 1.0 108.357 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.21 -52.67 22.1 Favored Glycine 0 CA--C 1.532 1.12 0 CA-C-N 115.95 -0.568 . . . . 1.0 112.61 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.85 -39.02 25.66 Favored Glycine 0 CA--C 1.531 1.046 0 CA-C-N 117.253 0.526 . . . . 1.0 112.037 179.854 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.6 mt -75.53 -55.76 10.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 112.042 0.386 . . . . 1.0 112.042 -178.322 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.463 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.4 OUTLIER -56.82 -30.0 31.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 120.741 0.305 . . . . 1.0 110.385 -177.202 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 32.7 tpt85 -65.35 -38.79 91.16 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.217 -1.031 . . . . 1.0 108.217 177.608 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.68 -39.05 92.75 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.273 -0.876 . . . . 1.0 109.592 179.113 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.6 mmt -60.36 -47.19 87.11 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.462 0.649 . . . . 1.0 109.359 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.8 mt -65.75 -41.6 91.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.806 -1.088 . . . . 1.0 109.584 178.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.35 -24.45 59.13 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.939 -0.865 . . . . 1.0 110.939 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.1 m -87.48 -35.28 18.32 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 121.285 0.564 . . . . 1.0 109.97 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -65.14 -48.53 73.22 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.09 -0.959 . . . . 1.0 111.677 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 42.5 mtm180 44.83 -159.59 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 115.986 -0.552 . . . . 1.0 111.883 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.0 mmtp -66.61 145.62 55.38 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.29 -0.414 . . . . 1.0 110.082 -179.609 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 68.7 m-20 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.035 -0.983 . . . . 1.0 110.726 -179.639 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.2 tpt . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 108.913 -0.773 . . . . 1.0 108.913 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -60.44 140.38 57.26 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 116.132 -0.486 . . . . 1.0 111.056 -179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 43.9 p90 -68.98 154.1 42.66 Favored 'General case' 0 CA--C 1.528 0.111 0 CA-C-N 116.008 -0.542 . . . . 1.0 110.172 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.409 ' C ' ' H ' ' A' ' 6' ' ' ILE . 76.3 m-85 -65.65 137.69 57.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.71 -0.677 . . . . 1.0 110.599 -179.629 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 29.8 p -63.5 -4.64 2.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.224 -0.898 . . . . 1.0 110.393 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.412 ' C ' ' H ' ' A' ' 8' ' ' LEU . 4.2 mp -103.5 137.62 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.125 -0.943 . . . . 1.0 109.299 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -79.24 31.37 0.22 Allowed 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 110.114 -0.328 . . . . 1.0 110.114 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.509 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.8 OUTLIER -52.95 167.64 0.39 Allowed Pre-proline 0 CA--C 1.549 0.904 0 CA-C-N 116.079 -0.509 . . . . 1.0 111.877 -178.612 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -102.55 5.92 0.44 Allowed 'Trans proline' 0 N--CA 1.487 1.117 0 C-N-CA 123.414 2.743 . . . . 1.0 110.206 179.086 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 25.1 mmtp 122.83 39.97 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 126.969 2.107 . . . . 1.0 107.886 -179.2 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -62.62 -69.15 0.28 Allowed 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.352 -0.84 . . . . 1.0 110.178 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.516 ' O ' HG12 ' A' ' 16' ' ' VAL . 89.6 mt -63.09 -34.88 78.56 Favored 'General case' 0 C--O 1.211 -0.951 0 N-CA-C 108.898 -0.779 . . . . 1.0 108.898 179.39 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.36 -52.6 22.97 Favored Glycine 0 CA--C 1.529 0.966 0 CA-C-N 116.116 -0.493 . . . . 1.0 113.13 -177.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -80.77 -39.94 13.07 Favored Glycine 0 CA--C 1.529 0.949 0 CA-C-N 117.491 0.645 . . . . 1.0 111.72 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.1 mt -72.48 -53.21 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 112.393 0.516 . . . . 1.0 112.393 -178.152 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.516 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.3 p -55.28 -30.98 25.87 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 C-N-CA 120.404 -0.518 . . . . 1.0 110.816 -177.274 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -66.53 -35.63 80.71 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 108.332 -0.988 . . . . 1.0 108.332 177.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.58 -39.36 94.19 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.577 -0.738 . . . . 1.0 109.459 178.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 10.4 mmt -60.18 -46.97 87.9 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.535 -0.757 . . . . 1.0 109.706 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.8 mt -66.27 -42.64 88.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.674 -1.148 . . . . 1.0 109.829 179.398 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.87 -24.27 64.44 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.43 -1.068 . . . . 1.0 110.43 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -88.83 -29.54 19.62 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.169 0.509 . . . . 1.0 109.855 179.415 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -66.35 -49.79 65.75 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 115.392 -0.822 . . . . 1.0 111.035 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 49.7 mtm-85 49.53 -178.89 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 115.538 -0.755 . . . . 1.0 111.857 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -65.39 135.96 55.9 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 115.96 -0.564 . . . . 1.0 110.345 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 41.2 p-10 . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 118.041 -0.981 . . . . 1.0 110.764 -179.976 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 43.0 tpp . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.155 -0.683 . . . . 1.0 109.155 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -148.62 145.48 27.79 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 109.451 -0.574 . . . . 1.0 109.451 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -161.23 175.35 12.41 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.016 0.436 . . . . 1.0 110.64 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 43.0 p90 -149.11 161.55 41.74 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.937 -0.574 . . . . 1.0 109.858 179.212 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.2 t -135.62 -5.03 2.25 Favored 'General case' 0 N--CA 1.48 1.047 0 CA-C-O 121.972 0.892 . . . . 1.0 108.989 179.029 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.8 mt -68.29 -3.89 2.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 113.89 -1.505 . . . . 1.0 109.867 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 48.4 mttt 52.36 30.03 7.59 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 114.867 -1.06 . . . . 1.0 109.257 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.528 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.5 OUTLIER -61.63 169.14 2.67 Favored Pre-proline 0 N--CA 1.443 -0.82 0 CA-C-N 113.406 -1.725 . . . . 1.0 111.705 -178.05 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -105.4 63.58 0.02 OUTLIER 'Trans proline' 0 N--CA 1.482 0.821 0 C-N-CA 123.569 2.846 . . . . 1.0 108.898 176.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt 58.26 45.82 16.61 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 115.299 -0.864 . . . . 1.0 111.01 -178.284 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -64.32 -73.8 0.11 Allowed 'General case' 0 N--CA 1.472 0.669 0 CA-C-O 121.301 0.572 . . . . 1.0 109.688 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.472 ' O ' HG12 ' A' ' 16' ' ' VAL . 87.3 mt -64.14 -34.59 78.41 Favored 'General case' 0 C--O 1.214 -0.774 0 CA-C-N 115.291 -0.868 . . . . 1.0 109.141 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -48.49 -50.15 24.97 Favored Glycine 0 CA--C 1.528 0.897 0 CA-C-N 116.153 -0.476 . . . . 1.0 112.814 -177.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.22 -41.93 9.01 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 117.468 0.634 . . . . 1.0 112.072 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.41 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 91.2 mt -72.05 -49.73 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 112.845 0.683 . . . . 1.0 112.845 -177.8 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.472 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.4 p -55.38 -32.33 29.18 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.474 0 C-N-CA 120.45 -0.5 . . . . 1.0 111.1 -176.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 87.4 mtm180 -65.57 -35.2 80.15 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 108.31 -0.996 . . . . 1.0 108.31 177.555 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.41 ' HB3' ' O ' ' A' ' 15' ' ' ILE . . . -63.01 -39.13 93.82 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.525 -0.761 . . . . 1.0 109.304 179.24 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.6 mmt -60.77 -46.61 89.8 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.646 -0.706 . . . . 1.0 109.759 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.3 mt -65.52 -41.91 92.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 114.591 -1.186 . . . . 1.0 110.313 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.62 -27.92 61.96 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 110.401 -1.08 . . . . 1.0 110.401 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.2 t -73.24 -35.61 66.28 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.896 0.855 . . . . 1.0 109.257 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -61.07 -40.3 93.15 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.225 -1.352 . . . . 1.0 110.969 -178.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 24.0 mmm180 -54.08 -38.71 65.6 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.214 -0.448 . . . . 1.0 110.627 -178.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -62.81 136.86 58.08 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 109.798 -0.445 . . . . 1.0 109.798 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.5 t0 . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.847 -1.073 . . . . 1.0 111.051 -179.596 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.6 ttt . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 108.902 -0.777 . . . . 1.0 108.902 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 47.3 mmtm -67.11 131.76 46.46 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 109.571 -0.529 . . . . 1.0 109.571 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.458 ' CD1' ' N ' ' A' ' 4' ' ' TYR . 51.1 p90 -112.45 -42.0 3.76 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 122.84 0.456 . . . . 1.0 110.482 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.458 ' N ' ' CD1' ' A' ' 3' ' ' PHE . 36.3 p90 -66.24 -35.64 80.95 Favored 'General case' 0 C--O 1.222 -0.382 0 CA-C-N 116.367 -0.379 . . . . 1.0 110.988 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.1 t 44.32 42.77 5.52 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 114.265 1.209 . . . . 1.0 114.265 178.058 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.412 HG22 ' H ' ' A' ' 8' ' ' LEU . 29.6 mt -133.78 144.49 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.781 -1.192 . . . . 1.0 107.781 179.22 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -72.84 17.48 0.12 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.063 0.394 . . . . 1.0 112.063 -178.475 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.586 HD13 ' H ' ' A' ' 11' ' ' PHE . 2.7 pp -62.08 168.84 3.32 Favored Pre-proline 0 CA--C 1.543 0.707 0 C-N-CA 122.862 0.465 . . . . 1.0 110.648 -179.679 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -104.21 64.1 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.373 0 C-N-CA 123.475 2.784 . . . . 1.0 111.802 -179.147 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 16.1 ttmm 58.31 54.91 5.35 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-O 121.174 0.511 . . . . 1.0 110.481 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PHE . . . . . 0.586 ' H ' HD13 ' A' ' 8' ' ' LEU . 9.0 t80 -59.93 -79.04 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 115.54 -0.754 . . . . 1.0 110.96 -179.112 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.485 ' O ' HG12 ' A' ' 16' ' ' VAL . 86.0 mt -65.1 -37.74 88.44 Favored 'General case' 0 C--O 1.212 -0.868 0 CA-C-N 115.576 -0.738 . . . . 1.0 109.015 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.85 -45.85 40.33 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-N 115.997 -0.547 . . . . 1.0 112.688 -178.137 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.45 -41.34 9.19 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 111.607 -0.597 . . . . 1.0 111.607 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.4 mt -74.07 -54.85 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 112.121 0.415 . . . . 1.0 112.121 -178.161 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.485 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.7 OUTLIER -56.65 -31.3 34.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.102 0.477 . . . . 1.0 110.703 -177.114 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -65.52 -37.05 85.62 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.66 -0.867 . . . . 1.0 108.66 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.84 -40.07 96.33 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.022 -0.99 . . . . 1.0 109.24 178.475 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.1 mmt -60.57 -47.26 86.99 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.519 -0.764 . . . . 1.0 109.81 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.0 mt -65.84 -40.57 91.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 114.68 -1.145 . . . . 1.0 109.989 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.24 -26.92 59.64 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.726 -0.949 . . . . 1.0 110.726 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.9 m -87.42 -43.2 12.26 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 121.193 0.52 . . . . 1.0 110.344 179.385 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -66.75 -49.11 67.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.407 -0.815 . . . . 1.0 111.19 -178.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 52.9 mtp180 48.38 35.2 5.41 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.315 -0.857 . . . . 1.0 111.917 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 68.3 mttm 53.3 41.51 32.12 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.24 -0.436 . . . . 1.0 111.106 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 36.6 t70 . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.209 -0.901 . . . . 1.0 110.421 179.942 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 . . . . . 0 N--CA 1.467 0.408 0 CA-C-O 120.929 0.395 . . . . 1.0 110.524 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.3 t -62.0 -18.61 61.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.271 0.557 . . . . 1.0 110.258 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.454 ' C ' ' H ' ' A' ' 8' ' ' LEU . 3.9 mp -79.6 138.04 20.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.105 -0.952 . . . . 1.0 108.995 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -77.44 23.73 0.21 Allowed 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.865 -0.42 . . . . 1.0 109.865 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.511 ' C ' HD12 ' A' ' 8' ' ' LEU . 2.5 pp -54.39 167.97 0.51 Allowed Pre-proline 0 N--CA 1.445 -0.698 0 CA-C-N 116.279 -0.419 . . . . 1.0 111.335 -179.288 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.462 ' CD ' ' H ' ' A' ' 10' ' ' LYS . 89.2 Cg_endo -92.42 -49.09 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.359 0 C-N-CA 122.271 1.981 . . . . 1.0 108.663 178.468 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . 0.462 ' H ' ' CD ' ' A' ' 9' ' ' PRO . 59.1 pttt -173.4 32.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 114.649 -1.159 . . . . 1.0 108.313 177.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -49.79 -73.44 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 115.228 -0.896 . . . . 1.0 111.381 -178.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.519 ' O ' HG12 ' A' ' 16' ' ' VAL . 96.4 mt -63.31 -38.42 91.1 Favored 'General case' 0 C--O 1.211 -0.934 0 N-CA-C 108.639 -0.874 . . . . 1.0 108.639 178.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.15 -51.9 28.98 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.031 -0.532 . . . . 1.0 113.149 -177.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -79.54 -37.66 23.07 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.654 -0.578 . . . . 1.0 111.654 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.6 mt -76.2 -56.39 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 112.199 0.444 . . . . 1.0 112.199 -178.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.519 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.8 OUTLIER -54.91 -31.63 25.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 120.763 -0.375 . . . . 1.0 111.059 -176.911 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.1 mmt180 -66.5 -35.19 79.64 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 108.318 -0.993 . . . . 1.0 108.318 177.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.05 -39.44 94.08 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.661 -0.7 . . . . 1.0 109.43 178.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.8 mmt -60.33 -48.11 83.14 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.557 -0.747 . . . . 1.0 109.559 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.51 -42.06 87.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 114.682 -1.145 . . . . 1.0 109.7 179.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.8 -23.2 63.04 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.57 -1.012 . . . . 1.0 110.57 179.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.8 m -90.27 -27.32 19.54 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 121.145 0.498 . . . . 1.0 109.662 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -69.88 -49.59 50.79 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 115.456 -0.793 . . . . 1.0 110.235 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 . . . . . 0 CA--C 1.536 0.405 0 CA-C-N 115.101 -0.954 . . . . 1.0 112.181 179.122 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 42.3 p90 . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.987 0.422 . . . . 1.0 110.251 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 68.8 p -129.32 -6.12 4.81 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-O 122.066 0.936 . . . . 1.0 108.873 178.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.444 ' C ' ' H ' ' A' ' 8' ' ' LEU . 5.6 mt -76.51 145.84 9.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 113.68 -1.6 . . . . 1.0 108.821 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 62.3 mttp -78.47 23.81 0.29 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 109.855 -0.424 . . . . 1.0 109.855 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.462 ' O ' HD12 ' A' ' 8' ' ' LEU . 2.0 pp -55.06 169.09 0.45 Allowed Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 122.921 0.489 . . . . 1.0 111.813 -178.503 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -106.26 65.29 0.02 OUTLIER 'Trans proline' 0 N--CA 1.487 1.145 0 C-N-CA 123.576 2.85 . . . . 1.0 110.429 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 99.6 mttt 55.14 54.05 9.34 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 116.335 -0.393 . . . . 1.0 110.465 -178.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PHE . . . . . 0.403 ' H ' HD13 ' A' ' 8' ' ' LEU . 12.6 t80 -56.01 -76.63 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.246 0.546 . . . . 1.0 110.372 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.479 ' O ' HG12 ' A' ' 16' ' ' VAL . 95.7 mt -66.67 -37.37 84.63 Favored 'General case' 0 C--O 1.21 -1.003 0 CA-C-N 115.323 -0.853 . . . . 1.0 108.939 179.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.36 -44.54 44.81 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 121.358 -0.448 . . . . 1.0 112.687 -178.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.65 -43.0 8.02 Favored Glycine 0 CA--C 1.53 0.996 0 N-CA-C 111.521 -0.631 . . . . 1.0 111.521 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.6 mt -73.88 -53.59 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 N-CA-C 112.284 0.476 . . . . 1.0 112.284 -178.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.479 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.5 OUTLIER -57.89 -30.46 38.26 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.665 0 N-CA-C 109.925 -0.398 . . . . 1.0 109.925 -177.374 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 26.3 tpt180 -62.43 -39.31 92.92 Favored 'General case' 0 CA--C 1.518 -0.273 0 N-CA-C 108.595 -0.891 . . . . 1.0 108.595 177.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.99 -40.08 94.4 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 115.471 -0.786 . . . . 1.0 109.418 179.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 21.9 mmt -61.59 -44.09 97.65 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.53 -0.759 . . . . 1.0 110.361 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.1 mt -65.33 -42.79 92.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.423 -0.808 . . . . 1.0 111.174 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.38 -29.76 72.39 Favored Glycine 0 N--CA 1.462 0.419 0 N-CA-C 110.143 -1.183 . . . . 1.0 110.143 179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.5 m -78.06 -49.19 14.44 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 121.518 0.675 . . . . 1.0 109.4 178.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -64.32 -73.02 0.13 Allowed 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 114.864 -1.062 . . . . 1.0 110.811 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 45.4 ptt85 . . . . . 0 N--CA 1.483 1.178 0 C-N-CA 123.788 0.835 . . . . 1.0 112.867 -179.901 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.473 0.69 0 N-CA-C 111.752 0.279 . . . . 1.0 111.752 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 24.9 p 66.32 14.83 9.87 Favored 'General case' 0 N--CA 1.466 0.347 0 O-C-N 123.818 0.699 . . . . 1.0 110.991 -178.561 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.43 ' C ' ' H ' ' A' ' 8' ' ' LEU . 22.7 mt -121.96 138.39 52.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 108.115 -1.068 . . . . 1.0 108.115 179.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -75.32 23.0 0.11 Allowed 'General case' 0 N--CA 1.469 0.501 0 O-C-N 122.41 -0.181 . . . . 1.0 110.962 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.537 HD13 ' H ' ' A' ' 11' ' ' PHE . 2.8 pp -58.31 167.65 1.59 Allowed Pre-proline 0 CA--C 1.545 0.758 0 C-N-CA 122.309 0.244 . . . . 1.0 111.24 -179.458 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_endo -106.37 67.02 0.02 OUTLIER 'Trans proline' 0 N--CA 1.49 1.32 0 C-N-CA 123.648 2.898 . . . . 1.0 110.774 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 68.1 mttm 54.36 54.83 8.87 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 121.068 0.461 . . . . 1.0 110.188 -178.444 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PHE . . . . . 0.537 ' H ' HD13 ' A' ' 8' ' ' LEU . 9.4 t80 -54.33 -83.4 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 115.869 -0.605 . . . . 1.0 110.889 -179.071 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.523 ' O ' HG12 ' A' ' 16' ' ' VAL . 94.7 mt -60.79 -33.61 73.24 Favored 'General case' 0 C--O 1.214 -0.787 0 N-CA-C 109.111 -0.7 . . . . 1.0 109.111 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.36 -43.14 43.45 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.601 -0.599 . . . . 1.0 111.601 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -84.4 -48.96 4.84 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 112.067 -0.413 . . . . 1.0 112.067 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 3.5 mp -70.28 -46.6 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 112.645 0.609 . . . . 1.0 112.645 -177.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.523 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.4 p -56.82 -30.98 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 C-N-CA 120.042 -0.663 . . . . 1.0 111.005 -176.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -65.96 -36.1 82.39 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.315 -0.994 . . . . 1.0 108.315 177.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.28 -39.56 94.93 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.677 -0.692 . . . . 1.0 109.601 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 9.3 mmt -60.38 -48.54 81.32 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 115.759 -0.655 . . . . 1.0 109.91 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 98.1 mt -66.17 -42.67 88.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.731 -1.122 . . . . 1.0 110.268 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.32 -26.22 65.88 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.358 -1.097 . . . . 1.0 110.358 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -88.0 -39.43 14.69 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.257 0.551 . . . . 1.0 110.416 179.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -64.6 -48.26 75.58 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.347 -0.842 . . . . 1.0 111.504 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 39.7 mtm180 . . . . . 0 CA--C 1.539 0.543 0 CA-C-N 115.71 -0.677 . . . . 1.0 112.034 -179.875 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 27.4 m-85 . . . . . 0 N--CA 1.472 0.639 0 N-CA-C 110.189 -0.301 . . . . 1.0 110.189 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.3 p 57.37 20.55 6.02 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 115.476 -0.783 . . . . 1.0 111.046 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 28.0 mt -124.12 134.45 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 CA-C-N 114.548 -1.205 . . . . 1.0 107.754 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -76.41 38.85 0.19 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.753 0.311 . . . . 1.0 110.719 -178.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.502 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.4 OUTLIER -70.58 169.0 15.61 Favored Pre-proline 0 CA--C 1.548 0.893 0 CA-C-N 116.522 -0.308 . . . . 1.0 111.765 -178.747 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -106.81 56.88 0.01 OUTLIER 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 123.847 3.031 . . . . 1.0 108.038 176.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 62.9 mttp 62.96 48.12 4.04 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 114.662 -1.154 . . . . 1.0 110.268 -177.155 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -64.51 -70.12 0.24 Allowed 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.276 0.56 . . . . 1.0 110.271 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.55 ' O ' HG12 ' A' ' 16' ' ' VAL . 86.7 mt -62.36 -33.69 75.21 Favored 'General case' 0 C--O 1.212 -0.883 0 CA-C-N 115.41 -0.814 . . . . 1.0 109.131 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -48.88 -53.5 17.77 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 121.281 -0.485 . . . . 1.0 113.193 -177.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.56 -40.28 11.2 Favored Glycine 0 N--CA 1.47 0.964 0 CA-C-N 117.529 0.665 . . . . 1.0 111.758 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.406 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 95.8 mt -71.12 -51.27 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 N-CA-C 112.363 0.505 . . . . 1.0 112.363 -177.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.55 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.6 p -56.33 -30.56 30.74 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.538 0 C-N-CA 120.331 -0.548 . . . . 1.0 110.655 -177.484 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 18.8 mmm180 -65.23 -36.67 84.86 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.377 -0.971 . . . . 1.0 108.377 177.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.406 ' HB3' ' O ' ' A' ' 15' ' ' ILE . . . -63.78 -39.19 93.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.257 -0.883 . . . . 1.0 109.635 179.069 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.9 mmt -60.8 -45.8 93.01 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.639 -0.71 . . . . 1.0 109.867 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.9 mt -65.23 -42.2 93.62 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 114.802 -1.09 . . . . 1.0 110.533 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.4 -31.68 70.74 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 109.971 -1.252 . . . . 1.0 109.971 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.5 t -73.1 -37.31 66.78 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.487 0.66 . . . . 1.0 109.715 178.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -59.4 -48.59 81.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 114.746 -1.116 . . . . 1.0 111.421 -178.097 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 10.3 ptp85 . . . . . 0 N--CA 1.471 0.623 0 CA-C-O 120.839 0.352 . . . . 1.0 110.475 179.756 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 41.8 p90 . . . . . 0 N--CA 1.467 0.381 0 CA-C-O 121.068 0.461 . . . . 1.0 110.469 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 81.3 p -129.0 11.97 6.1 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.325 -0.852 . . . . 1.0 108.77 178.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.446 ' C ' ' H ' ' A' ' 8' ' ' LEU . 7.4 mt -102.18 142.93 15.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.208 -1.36 . . . . 1.0 108.969 -178.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -66.68 11.32 0.1 Allowed 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 111.937 0.347 . . . . 1.0 111.937 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.547 ' C ' HD12 ' A' ' 8' ' ' LEU . 3.6 pp -58.01 169.93 0.8 Allowed Pre-proline 0 CA--C 1.538 0.503 0 CA-C-O 119.539 -0.267 . . . . 1.0 111.221 -179.145 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.404 ' CG ' ' H ' ' A' ' 10' ' ' LYS . 83.9 Cg_endo -96.73 -63.12 0.01 OUTLIER 'Trans proline' 0 N--CA 1.489 1.224 0 C-N-CA 122.752 2.301 . . . . 1.0 109.17 178.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . 0.404 ' H ' ' CG ' ' A' ' 9' ' ' PRO . 54.2 mtmt -157.75 36.68 0.26 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 107.908 -1.145 . . . . 1.0 107.908 178.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 23.0 t80 -48.44 -75.14 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.561 -0.745 . . . . 1.0 111.464 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.474 ' O ' HG12 ' A' ' 16' ' ' VAL . 90.9 mt -65.0 -38.93 92.57 Favored 'General case' 0 C--O 1.211 -0.943 0 N-CA-C 108.803 -0.814 . . . . 1.0 108.803 179.178 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.42 -50.95 33.72 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 121.313 -0.47 . . . . 1.0 112.874 -178.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.71 -38.81 26.74 Favored Glycine 0 CA--C 1.529 0.942 0 N-CA-C 111.685 -0.566 . . . . 1.0 111.685 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.78 -57.33 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 122.571 0.349 . . . . 1.0 111.895 -178.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.474 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.5 OUTLIER -55.13 -30.45 24.18 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 C-N-CA 120.962 -0.295 . . . . 1.0 110.542 -177.274 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 25.0 tpt180 -64.68 -39.45 93.69 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 108.466 -0.939 . . . . 1.0 108.466 177.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.21 -39.76 93.85 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.112 -0.949 . . . . 1.0 109.741 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.4 mmt -60.43 -47.76 84.7 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.667 -0.697 . . . . 1.0 109.669 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.4 mt -66.02 -42.18 89.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.669 -1.151 . . . . 1.0 110.027 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -60.99 -25.85 64.78 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.413 -1.075 . . . . 1.0 110.413 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.4 m -87.87 -35.3 17.83 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.253 0.549 . . . . 1.0 110.093 179.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -66.58 -49.07 67.59 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.361 -0.836 . . . . 1.0 111.378 -178.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.7 mtp85 . . . . . 0 CA--C 1.537 0.445 0 CA-C-N 115.839 -0.619 . . . . 1.0 111.594 -179.944 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 75.5 m-85 . . . . . 0 N--CA 1.465 0.32 0 N-CA-C 109.7 -0.481 . . . . 1.0 109.7 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.1 p -65.12 -10.0 27.28 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.56 -0.746 . . . . 1.0 110.087 -179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.444 ' C ' ' H ' ' A' ' 8' ' ' LEU . 3.8 mp -98.1 138.73 21.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 114.924 -1.034 . . . . 1.0 109.665 -179.331 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 61.0 pttt -67.52 9.16 0.27 Allowed 'General case' 0 CA--C 1.535 0.366 0 CA-C-N 116.352 -0.385 . . . . 1.0 111.18 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.549 ' C ' HD12 ' A' ' 8' ' ' LEU . 3.1 pp -48.61 165.48 0.25 Allowed Pre-proline 0 CA--C 1.543 0.704 0 N-CA-C 112.349 0.5 . . . . 1.0 112.349 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.482 ' CD ' ' H ' ' A' ' 10' ' ' LYS . 49.7 Cg_endo -95.39 -51.41 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.364 0 C-N-CA 122.97 2.447 . . . . 1.0 109.393 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . 0.482 ' H ' ' CD ' ' A' ' 9' ' ' PRO . 60.3 pttt -167.58 32.01 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 114.972 -1.013 . . . . 1.0 108.64 178.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 40.6 t80 -55.66 -73.12 0.06 Allowed 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.185 -0.916 . . . . 1.0 111.357 -178.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.514 ' O ' HG12 ' A' ' 16' ' ' VAL . 92.9 mt -63.29 -38.85 92.76 Favored 'General case' 0 C--O 1.211 -0.932 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 179.288 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.12 -52.62 26.3 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 121.243 -0.503 . . . . 1.0 112.818 -177.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.09 -39.34 27.66 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.686 -0.566 . . . . 1.0 111.686 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.417 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 95.6 mt -76.01 -56.85 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 112.357 0.503 . . . . 1.0 112.357 -178.218 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.514 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.8 OUTLIER -53.99 -31.4 21.06 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.464 0 CA-C-O 121.148 0.499 . . . . 1.0 110.889 -177.279 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 59.8 ttt85 -67.33 -36.62 81.82 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 108.392 -0.966 . . . . 1.0 108.392 178.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.417 ' HB3' ' O ' ' A' ' 15' ' ' ILE . . . -63.22 -39.52 94.86 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.046 -0.979 . . . . 1.0 109.466 179.08 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 9.8 mmt -60.11 -48.58 81.11 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.646 0.736 . . . . 1.0 109.568 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.0 mt -66.41 -41.66 88.97 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.411 -1.268 . . . . 1.0 109.795 179.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -74.21 -5.32 71.16 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.437 -0.801 . . . . 1.0 111.948 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 38.6 t -93.59 -30.94 14.72 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 121.716 0.769 . . . . 1.0 108.957 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.95 -45.78 33.22 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 114.27 -1.332 . . . . 1.0 108.751 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 85.8 mtt-85 . . . . . 0 CA--C 1.535 0.377 0 CA-C-N 114.971 -1.013 . . . . 1.0 112.193 179.65 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 34.3 p90 . . . . . 0 CA--C 1.528 0.126 0 CA-C-O 121.053 0.454 . . . . 1.0 110.833 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 70.6 p -127.03 20.99 6.88 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.802 0.81 . . . . 1.0 109.586 179.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.428 ' C ' ' H ' ' A' ' 8' ' ' LEU . 34.1 mt -113.35 147.65 16.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 114.241 -1.345 . . . . 1.0 109.079 -178.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -76.11 21.02 0.18 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-O 120.753 0.311 . . . . 1.0 110.77 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.52 HD13 ' H ' ' A' ' 11' ' ' PHE . 2.6 pp -59.39 167.25 2.4 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-N 116.302 -0.408 . . . . 1.0 111.503 -179.079 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -105.0 64.73 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 123.532 2.822 . . . . 1.0 110.913 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 97.6 mttt 54.95 55.81 7.33 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.274 0.559 . . . . 1.0 109.733 -178.464 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PHE . . . . . 0.52 ' H ' HD13 ' A' ' 8' ' ' LEU . 12.5 t80 -53.53 -78.79 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.471 -0.786 . . . . 1.0 111.091 -178.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.463 ' O ' HG12 ' A' ' 16' ' ' VAL . 85.8 mt -65.31 -38.13 89.23 Favored 'General case' 0 C--O 1.211 -0.938 0 N-CA-C 108.357 -0.979 . . . . 1.0 108.357 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.21 -52.67 22.1 Favored Glycine 0 CA--C 1.532 1.12 0 CA-C-N 115.95 -0.568 . . . . 1.0 112.61 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.85 -39.02 25.66 Favored Glycine 0 CA--C 1.531 1.046 0 CA-C-N 117.253 0.526 . . . . 1.0 112.037 179.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.6 mt -75.53 -55.76 10.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 112.042 0.386 . . . . 1.0 112.042 -178.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.463 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.4 OUTLIER -56.82 -30.0 31.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 120.741 0.305 . . . . 1.0 110.385 -177.202 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 32.7 tpt85 -65.35 -38.79 91.16 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.217 -1.031 . . . . 1.0 108.217 177.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.68 -39.05 92.75 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.273 -0.876 . . . . 1.0 109.592 179.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.6 mmt -60.36 -47.19 87.11 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.462 0.649 . . . . 1.0 109.359 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.8 mt -65.75 -41.6 91.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.806 -1.088 . . . . 1.0 109.584 178.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.35 -24.45 59.13 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.939 -0.865 . . . . 1.0 110.939 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.1 m -87.48 -35.28 18.32 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 121.285 0.564 . . . . 1.0 109.97 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -65.14 -48.53 73.22 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.09 -0.959 . . . . 1.0 111.677 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 42.5 mtm180 . . . . . 0 CA--C 1.537 0.471 0 CA-C-N 115.986 -0.552 . . . . 1.0 111.883 179.524 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.409 ' C ' ' H ' ' A' ' 6' ' ' ILE . 76.3 m-85 . . . . . 0 N--CA 1.464 0.273 0 CA-C-O 121.284 0.564 . . . . 1.0 110.599 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 29.8 p -63.5 -4.64 2.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.224 -0.898 . . . . 1.0 110.393 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.412 ' C ' ' H ' ' A' ' 8' ' ' LEU . 4.2 mp -103.5 137.62 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.125 -0.943 . . . . 1.0 109.299 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -79.24 31.37 0.22 Allowed 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 110.114 -0.328 . . . . 1.0 110.114 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.509 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.8 OUTLIER -52.95 167.64 0.39 Allowed Pre-proline 0 CA--C 1.549 0.904 0 CA-C-N 116.079 -0.509 . . . . 1.0 111.877 -178.612 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -102.55 5.92 0.44 Allowed 'Trans proline' 0 N--CA 1.487 1.117 0 C-N-CA 123.414 2.743 . . . . 1.0 110.206 179.086 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 25.1 mmtp 122.83 39.97 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 126.969 2.107 . . . . 1.0 107.886 -179.2 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -62.62 -69.15 0.28 Allowed 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.352 -0.84 . . . . 1.0 110.178 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.516 ' O ' HG12 ' A' ' 16' ' ' VAL . 89.6 mt -63.09 -34.88 78.56 Favored 'General case' 0 C--O 1.211 -0.951 0 N-CA-C 108.898 -0.779 . . . . 1.0 108.898 179.39 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.36 -52.6 22.97 Favored Glycine 0 CA--C 1.529 0.966 0 CA-C-N 116.116 -0.493 . . . . 1.0 113.13 -177.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -80.77 -39.94 13.07 Favored Glycine 0 CA--C 1.529 0.949 0 CA-C-N 117.491 0.645 . . . . 1.0 111.72 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.1 mt -72.48 -53.21 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 112.393 0.516 . . . . 1.0 112.393 -178.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.516 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.3 p -55.28 -30.98 25.87 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 C-N-CA 120.404 -0.518 . . . . 1.0 110.816 -177.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -66.53 -35.63 80.71 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 108.332 -0.988 . . . . 1.0 108.332 177.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.58 -39.36 94.19 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.577 -0.738 . . . . 1.0 109.459 178.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 10.4 mmt -60.18 -46.97 87.9 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.535 -0.757 . . . . 1.0 109.706 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.8 mt -66.27 -42.64 88.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.674 -1.148 . . . . 1.0 109.829 179.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.87 -24.27 64.44 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.43 -1.068 . . . . 1.0 110.43 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -88.83 -29.54 19.62 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.169 0.509 . . . . 1.0 109.855 179.415 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -66.35 -49.79 65.75 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 115.392 -0.822 . . . . 1.0 111.035 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 49.7 mtm-85 . . . . . 0 CA--C 1.535 0.394 0 CA-C-N 115.538 -0.755 . . . . 1.0 111.857 179.88 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 43.0 p90 . . . . . 0 N--CA 1.47 0.558 0 N-CA-C 109.858 -0.423 . . . . 1.0 109.858 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.2 t -135.62 -5.03 2.25 Favored 'General case' 0 N--CA 1.48 1.047 0 CA-C-O 121.972 0.892 . . . . 1.0 108.989 179.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.8 mt -68.29 -3.89 2.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 113.89 -1.505 . . . . 1.0 109.867 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 48.4 mttt 52.36 30.03 7.59 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 114.867 -1.06 . . . . 1.0 109.257 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.528 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.5 OUTLIER -61.63 169.14 2.67 Favored Pre-proline 0 N--CA 1.443 -0.82 0 CA-C-N 113.406 -1.725 . . . . 1.0 111.705 -178.05 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -105.4 63.58 0.02 OUTLIER 'Trans proline' 0 N--CA 1.482 0.821 0 C-N-CA 123.569 2.846 . . . . 1.0 108.898 176.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt 58.26 45.82 16.61 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 115.299 -0.864 . . . . 1.0 111.01 -178.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -64.32 -73.8 0.11 Allowed 'General case' 0 N--CA 1.472 0.669 0 CA-C-O 121.301 0.572 . . . . 1.0 109.688 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.472 ' O ' HG12 ' A' ' 16' ' ' VAL . 87.3 mt -64.14 -34.59 78.41 Favored 'General case' 0 C--O 1.214 -0.774 0 CA-C-N 115.291 -0.868 . . . . 1.0 109.141 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -48.49 -50.15 24.97 Favored Glycine 0 CA--C 1.528 0.897 0 CA-C-N 116.153 -0.476 . . . . 1.0 112.814 -177.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.22 -41.93 9.01 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 117.468 0.634 . . . . 1.0 112.072 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.41 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 91.2 mt -72.05 -49.73 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 112.845 0.683 . . . . 1.0 112.845 -177.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.472 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.4 p -55.38 -32.33 29.18 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.474 0 C-N-CA 120.45 -0.5 . . . . 1.0 111.1 -176.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 87.4 mtm180 -65.57 -35.2 80.15 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 108.31 -0.996 . . . . 1.0 108.31 177.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.41 ' HB3' ' O ' ' A' ' 15' ' ' ILE . . . -63.01 -39.13 93.82 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.525 -0.761 . . . . 1.0 109.304 179.24 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.6 mmt -60.77 -46.61 89.8 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.646 -0.706 . . . . 1.0 109.759 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.3 mt -65.52 -41.91 92.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 114.591 -1.186 . . . . 1.0 110.313 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.62 -27.92 61.96 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 110.401 -1.08 . . . . 1.0 110.401 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.2 t -73.24 -35.61 66.28 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.896 0.855 . . . . 1.0 109.257 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -61.07 -40.3 93.15 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.225 -1.352 . . . . 1.0 110.969 -178.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 24.0 mmm180 . . . . . 0 N--CA 1.469 0.486 0 CA-C-N 116.214 -0.448 . . . . 1.0 110.627 -178.755 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 36.3 p90 . . . . . 0 C--O 1.222 -0.382 0 CA-C-O 119.899 -0.096 . . . . 1.0 110.988 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.1 t 44.32 42.77 5.52 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 114.265 1.209 . . . . 1.0 114.265 178.058 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.412 HG22 ' H ' ' A' ' 8' ' ' LEU . 29.6 mt -133.78 144.49 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.781 -1.192 . . . . 1.0 107.781 179.22 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -72.84 17.48 0.12 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.063 0.394 . . . . 1.0 112.063 -178.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.586 HD13 ' H ' ' A' ' 11' ' ' PHE . 2.7 pp -62.08 168.84 3.32 Favored Pre-proline 0 CA--C 1.543 0.707 0 C-N-CA 122.862 0.465 . . . . 1.0 110.648 -179.679 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -104.21 64.1 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.373 0 C-N-CA 123.475 2.784 . . . . 1.0 111.802 -179.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 16.1 ttmm 58.31 54.91 5.35 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-O 121.174 0.511 . . . . 1.0 110.481 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PHE . . . . . 0.586 ' H ' HD13 ' A' ' 8' ' ' LEU . 9.0 t80 -59.93 -79.04 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 115.54 -0.754 . . . . 1.0 110.96 -179.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.485 ' O ' HG12 ' A' ' 16' ' ' VAL . 86.0 mt -65.1 -37.74 88.44 Favored 'General case' 0 C--O 1.212 -0.868 0 CA-C-N 115.576 -0.738 . . . . 1.0 109.015 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.85 -45.85 40.33 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-N 115.997 -0.547 . . . . 1.0 112.688 -178.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.45 -41.34 9.19 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 111.607 -0.597 . . . . 1.0 111.607 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.4 mt -74.07 -54.85 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 112.121 0.415 . . . . 1.0 112.121 -178.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.485 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.7 OUTLIER -56.65 -31.3 34.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.102 0.477 . . . . 1.0 110.703 -177.114 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -65.52 -37.05 85.62 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.66 -0.867 . . . . 1.0 108.66 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.84 -40.07 96.33 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.022 -0.99 . . . . 1.0 109.24 178.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.1 mmt -60.57 -47.26 86.99 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.519 -0.764 . . . . 1.0 109.81 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.0 mt -65.84 -40.57 91.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 114.68 -1.145 . . . . 1.0 109.989 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.24 -26.92 59.64 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.726 -0.949 . . . . 1.0 110.726 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.9 m -87.42 -43.2 12.26 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 121.193 0.52 . . . . 1.0 110.344 179.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -66.75 -49.11 67.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.407 -0.815 . . . . 1.0 111.19 -178.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 52.9 mtp180 . . . . . 0 CA--C 1.535 0.395 0 CA-C-N 115.315 -0.857 . . . . 1.0 111.917 179.726 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.5 ttt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 108.931 -0.766 . . . . 1.0 108.931 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -62.61 -44.73 95.55 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.073 -0.512 . . . . 1.0 109.964 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.409 ' CD2' ' O ' ' A' ' 4' ' ' TYR . 75.6 t80 -164.3 153.0 13.12 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.028 -0.533 . . . . 1.0 109.66 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.409 ' O ' ' CD2' ' A' ' 3' ' ' PHE . 90.0 m-85 -75.44 127.43 33.11 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.929 0.395 . . . . 1.0 110.524 -179.698 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.3 t -62.0 -18.61 61.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.271 0.557 . . . . 1.0 110.258 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.454 ' C ' ' H ' ' A' ' 8' ' ' LEU . 3.9 mp -79.6 138.04 20.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.105 -0.952 . . . . 1.0 108.995 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -77.44 23.73 0.21 Allowed 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.865 -0.42 . . . . 1.0 109.865 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.511 ' C ' HD12 ' A' ' 8' ' ' LEU . 2.5 pp -54.39 167.97 0.51 Allowed Pre-proline 0 N--CA 1.445 -0.698 0 CA-C-N 116.279 -0.419 . . . . 1.0 111.335 -179.288 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.462 ' CD ' ' H ' ' A' ' 10' ' ' LYS . 89.2 Cg_endo -92.42 -49.09 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.359 0 C-N-CA 122.271 1.981 . . . . 1.0 108.663 178.468 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . 0.462 ' H ' ' CD ' ' A' ' 9' ' ' PRO . 59.1 pttt -173.4 32.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 114.649 -1.159 . . . . 1.0 108.313 177.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 40.1 t80 -49.79 -73.44 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 115.228 -0.896 . . . . 1.0 111.381 -178.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.519 ' O ' HG12 ' A' ' 16' ' ' VAL . 96.4 mt -63.31 -38.42 91.1 Favored 'General case' 0 C--O 1.211 -0.934 0 N-CA-C 108.639 -0.874 . . . . 1.0 108.639 178.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.15 -51.9 28.98 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.031 -0.532 . . . . 1.0 113.149 -177.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -79.54 -37.66 23.07 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.654 -0.578 . . . . 1.0 111.654 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.6 mt -76.2 -56.39 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 112.199 0.444 . . . . 1.0 112.199 -178.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.519 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.8 OUTLIER -54.91 -31.63 25.14 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 120.763 -0.375 . . . . 1.0 111.059 -176.911 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.1 mmt180 -66.5 -35.19 79.64 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 108.318 -0.993 . . . . 1.0 108.318 177.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.05 -39.44 94.08 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.661 -0.7 . . . . 1.0 109.43 178.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.8 mmt -60.33 -48.11 83.14 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.557 -0.747 . . . . 1.0 109.559 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.51 -42.06 87.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 114.682 -1.145 . . . . 1.0 109.7 179.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.8 -23.2 63.04 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.57 -1.012 . . . . 1.0 110.57 179.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.8 m -90.27 -27.32 19.54 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 121.145 0.498 . . . . 1.0 109.662 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -69.88 -49.59 50.79 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 115.456 -0.793 . . . . 1.0 110.235 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 46.94 79.49 0.06 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.101 -0.954 . . . . 1.0 112.181 179.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 64.7 tttp -62.34 -44.79 95.65 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.303 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 50.5 p-10 . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.816 -1.088 . . . . 1.0 110.284 179.868 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.1 ptt? . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 108.906 -0.775 . . . . 1.0 108.906 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -166.05 131.03 2.32 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.669 -0.493 . . . . 1.0 109.669 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -79.15 -174.2 3.99 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.299 0.571 . . . . 1.0 110.981 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 42.3 p90 -154.08 159.48 41.54 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.406 -0.815 . . . . 1.0 110.251 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 68.8 p -129.32 -6.12 4.81 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-O 122.066 0.936 . . . . 1.0 108.873 178.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.444 ' C ' ' H ' ' A' ' 8' ' ' LEU . 5.6 mt -76.51 145.84 9.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 113.68 -1.6 . . . . 1.0 108.821 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 62.3 mttp -78.47 23.81 0.29 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 109.855 -0.424 . . . . 1.0 109.855 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.462 ' O ' HD12 ' A' ' 8' ' ' LEU . 2.0 pp -55.06 169.09 0.45 Allowed Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 122.921 0.489 . . . . 1.0 111.813 -178.503 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -106.26 65.29 0.02 OUTLIER 'Trans proline' 0 N--CA 1.487 1.145 0 C-N-CA 123.576 2.85 . . . . 1.0 110.429 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 99.6 mttt 55.14 54.05 9.34 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 116.335 -0.393 . . . . 1.0 110.465 -178.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PHE . . . . . 0.403 ' H ' HD13 ' A' ' 8' ' ' LEU . 12.6 t80 -56.01 -76.63 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.246 0.546 . . . . 1.0 110.372 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.479 ' O ' HG12 ' A' ' 16' ' ' VAL . 95.7 mt -66.67 -37.37 84.63 Favored 'General case' 0 C--O 1.21 -1.003 0 CA-C-N 115.323 -0.853 . . . . 1.0 108.939 179.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.36 -44.54 44.81 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 121.358 -0.448 . . . . 1.0 112.687 -178.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.65 -43.0 8.02 Favored Glycine 0 CA--C 1.53 0.996 0 N-CA-C 111.521 -0.631 . . . . 1.0 111.521 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.6 mt -73.88 -53.59 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 N-CA-C 112.284 0.476 . . . . 1.0 112.284 -178.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.479 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.5 OUTLIER -57.89 -30.46 38.26 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.665 0 N-CA-C 109.925 -0.398 . . . . 1.0 109.925 -177.374 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 26.3 tpt180 -62.43 -39.31 92.92 Favored 'General case' 0 CA--C 1.518 -0.273 0 N-CA-C 108.595 -0.891 . . . . 1.0 108.595 177.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.99 -40.08 94.4 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 115.471 -0.786 . . . . 1.0 109.418 179.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 21.9 mmt -61.59 -44.09 97.65 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.53 -0.759 . . . . 1.0 110.361 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.1 mt -65.33 -42.79 92.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.423 -0.808 . . . . 1.0 111.174 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.38 -29.76 72.39 Favored Glycine 0 N--CA 1.462 0.419 0 N-CA-C 110.143 -1.183 . . . . 1.0 110.143 179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.5 m -78.06 -49.19 14.44 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 121.518 0.675 . . . . 1.0 109.4 178.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -64.32 -73.02 0.13 Allowed 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 114.864 -1.062 . . . . 1.0 110.811 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 45.4 ptt85 29.05 46.9 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.788 0.835 . . . . 1.0 112.867 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -62.98 135.19 57.16 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.716 -0.674 . . . . 1.0 110.303 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 53.3 p-10 . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.199 -0.905 . . . . 1.0 110.964 -179.968 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.0 mtt . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 108.978 -0.749 . . . . 1.0 108.978 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -66.58 121.01 14.4 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 109.604 -0.517 . . . . 1.0 109.604 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 52.8 t80 -64.7 -49.77 69.6 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 121.196 0.522 . . . . 1.0 110.412 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -72.26 -38.04 68.96 Favored 'General case' 0 N--CA 1.473 0.69 0 CA-C-N 115.381 -0.827 . . . . 1.0 111.752 -179.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 24.9 p 66.32 14.83 9.87 Favored 'General case' 0 N--CA 1.466 0.347 0 O-C-N 123.818 0.699 . . . . 1.0 110.991 -178.561 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.43 ' C ' ' H ' ' A' ' 8' ' ' LEU . 22.7 mt -121.96 138.39 52.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 108.115 -1.068 . . . . 1.0 108.115 179.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -75.32 23.0 0.11 Allowed 'General case' 0 N--CA 1.469 0.501 0 O-C-N 122.41 -0.181 . . . . 1.0 110.962 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.537 HD13 ' H ' ' A' ' 11' ' ' PHE . 2.8 pp -58.31 167.65 1.59 Allowed Pre-proline 0 CA--C 1.545 0.758 0 C-N-CA 122.309 0.244 . . . . 1.0 111.24 -179.458 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_endo -106.37 67.02 0.02 OUTLIER 'Trans proline' 0 N--CA 1.49 1.32 0 C-N-CA 123.648 2.898 . . . . 1.0 110.774 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 68.1 mttm 54.36 54.83 8.87 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 121.068 0.461 . . . . 1.0 110.188 -178.444 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PHE . . . . . 0.537 ' H ' HD13 ' A' ' 8' ' ' LEU . 9.4 t80 -54.33 -83.4 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 115.869 -0.605 . . . . 1.0 110.889 -179.071 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.523 ' O ' HG12 ' A' ' 16' ' ' VAL . 94.7 mt -60.79 -33.61 73.24 Favored 'General case' 0 C--O 1.214 -0.787 0 N-CA-C 109.111 -0.7 . . . . 1.0 109.111 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.36 -43.14 43.45 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.601 -0.599 . . . . 1.0 111.601 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -84.4 -48.96 4.84 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 112.067 -0.413 . . . . 1.0 112.067 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 3.5 mp -70.28 -46.6 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 112.645 0.609 . . . . 1.0 112.645 -177.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.523 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.4 p -56.82 -30.98 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 C-N-CA 120.042 -0.663 . . . . 1.0 111.005 -176.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -65.96 -36.1 82.39 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.315 -0.994 . . . . 1.0 108.315 177.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.28 -39.56 94.93 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.677 -0.692 . . . . 1.0 109.601 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 9.3 mmt -60.38 -48.54 81.32 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 115.759 -0.655 . . . . 1.0 109.91 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 98.1 mt -66.17 -42.67 88.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.731 -1.122 . . . . 1.0 110.268 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.32 -26.22 65.88 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.358 -1.097 . . . . 1.0 110.358 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -88.0 -39.43 14.69 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.257 0.551 . . . . 1.0 110.416 179.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -64.6 -48.26 75.58 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.347 -0.842 . . . . 1.0 111.504 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 39.7 mtm180 42.33 -163.65 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.71 -0.677 . . . . 1.0 112.034 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp 55.33 -169.04 0.08 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.228 -0.442 . . . . 1.0 110.708 -179.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 117.97 -1.014 . . . . 1.0 110.408 -179.928 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.1 ttt . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.044 -0.725 . . . . 1.0 109.044 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 62.5 tttp 56.97 90.22 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.124 -0.489 . . . . 1.0 110.79 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.434 ' CD2' ' O ' ' A' ' 3' ' ' PHE . 31.3 p90 -70.51 105.6 3.15 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 116.117 -0.492 . . . . 1.0 110.377 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 27.4 m-85 -73.01 -52.14 15.55 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 116.484 -0.325 . . . . 1.0 110.189 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.3 p 57.37 20.55 6.02 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 115.476 -0.783 . . . . 1.0 111.046 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 28.0 mt -124.12 134.45 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 CA-C-N 114.548 -1.205 . . . . 1.0 107.754 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -76.41 38.85 0.19 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.753 0.311 . . . . 1.0 110.719 -178.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.502 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.4 OUTLIER -70.58 169.0 15.61 Favored Pre-proline 0 CA--C 1.548 0.893 0 CA-C-N 116.522 -0.308 . . . . 1.0 111.765 -178.747 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -106.81 56.88 0.01 OUTLIER 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 123.847 3.031 . . . . 1.0 108.038 176.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 62.9 mttp 62.96 48.12 4.04 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 114.662 -1.154 . . . . 1.0 110.268 -177.155 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -64.51 -70.12 0.24 Allowed 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.276 0.56 . . . . 1.0 110.271 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.55 ' O ' HG12 ' A' ' 16' ' ' VAL . 86.7 mt -62.36 -33.69 75.21 Favored 'General case' 0 C--O 1.212 -0.883 0 CA-C-N 115.41 -0.814 . . . . 1.0 109.131 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -48.88 -53.5 17.77 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 121.281 -0.485 . . . . 1.0 113.193 -177.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -81.56 -40.28 11.2 Favored Glycine 0 N--CA 1.47 0.964 0 CA-C-N 117.529 0.665 . . . . 1.0 111.758 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.406 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 95.8 mt -71.12 -51.27 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 N-CA-C 112.363 0.505 . . . . 1.0 112.363 -177.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.55 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.6 p -56.33 -30.56 30.74 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.538 0 C-N-CA 120.331 -0.548 . . . . 1.0 110.655 -177.484 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 18.8 mmm180 -65.23 -36.67 84.86 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.377 -0.971 . . . . 1.0 108.377 177.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.406 ' HB3' ' O ' ' A' ' 15' ' ' ILE . . . -63.78 -39.19 93.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.257 -0.883 . . . . 1.0 109.635 179.069 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.9 mmt -60.8 -45.8 93.01 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.639 -0.71 . . . . 1.0 109.867 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.9 mt -65.23 -42.2 93.62 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 114.802 -1.09 . . . . 1.0 110.533 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.4 -31.68 70.74 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 109.971 -1.252 . . . . 1.0 109.971 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 6.5 t -73.1 -37.31 66.78 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.487 0.66 . . . . 1.0 109.715 178.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -59.4 -48.59 81.06 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 114.746 -1.116 . . . . 1.0 111.421 -178.097 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 10.3 ptp85 -80.63 160.21 25.14 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 120.839 0.352 . . . . 1.0 110.475 179.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.3 tmtt? -61.65 -48.32 81.37 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.927 -0.768 . . . . 1.0 108.927 -179.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 32.6 t70 . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 117.994 -1.003 . . . . 1.0 110.092 179.295 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 81.6 mtp . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 108.921 -0.77 . . . . 1.0 108.921 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -62.71 -41.97 99.41 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.137 -0.483 . . . . 1.0 110.062 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.8 p90 -78.14 -176.34 4.54 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.053 -0.521 . . . . 1.0 110.311 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -158.21 161.48 37.8 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 115.756 -0.656 . . . . 1.0 110.469 178.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 81.3 p -129.0 11.97 6.1 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.325 -0.852 . . . . 1.0 108.77 178.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.446 ' C ' ' H ' ' A' ' 8' ' ' LEU . 7.4 mt -102.18 142.93 15.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.208 -1.36 . . . . 1.0 108.969 -178.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -66.68 11.32 0.1 Allowed 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 111.937 0.347 . . . . 1.0 111.937 -179.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.547 ' C ' HD12 ' A' ' 8' ' ' LEU . 3.6 pp -58.01 169.93 0.8 Allowed Pre-proline 0 CA--C 1.538 0.503 0 CA-C-O 119.539 -0.267 . . . . 1.0 111.221 -179.145 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.404 ' CG ' ' H ' ' A' ' 10' ' ' LYS . 83.9 Cg_endo -96.73 -63.12 0.01 OUTLIER 'Trans proline' 0 N--CA 1.489 1.224 0 C-N-CA 122.752 2.301 . . . . 1.0 109.17 178.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . 0.404 ' H ' ' CG ' ' A' ' 9' ' ' PRO . 54.2 mtmt -157.75 36.68 0.26 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 107.908 -1.145 . . . . 1.0 107.908 178.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 23.0 t80 -48.44 -75.14 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.561 -0.745 . . . . 1.0 111.464 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.474 ' O ' HG12 ' A' ' 16' ' ' VAL . 90.9 mt -65.0 -38.93 92.57 Favored 'General case' 0 C--O 1.211 -0.943 0 N-CA-C 108.803 -0.814 . . . . 1.0 108.803 179.178 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.42 -50.95 33.72 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 121.313 -0.47 . . . . 1.0 112.874 -178.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.71 -38.81 26.74 Favored Glycine 0 CA--C 1.529 0.942 0 N-CA-C 111.685 -0.566 . . . . 1.0 111.685 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.78 -57.33 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 122.571 0.349 . . . . 1.0 111.895 -178.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.474 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.5 OUTLIER -55.13 -30.45 24.18 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 C-N-CA 120.962 -0.295 . . . . 1.0 110.542 -177.274 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 25.0 tpt180 -64.68 -39.45 93.69 Favored 'General case' 0 N--CA 1.453 -0.284 0 N-CA-C 108.466 -0.939 . . . . 1.0 108.466 177.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.21 -39.76 93.85 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.112 -0.949 . . . . 1.0 109.741 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.4 mmt -60.43 -47.76 84.7 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.667 -0.697 . . . . 1.0 109.669 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.4 mt -66.02 -42.18 89.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.669 -1.151 . . . . 1.0 110.027 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -60.99 -25.85 64.78 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.413 -1.075 . . . . 1.0 110.413 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.4 m -87.87 -35.3 17.83 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.253 0.549 . . . . 1.0 110.093 179.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -66.58 -49.07 67.59 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.361 -0.836 . . . . 1.0 111.378 -178.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.7 mtp85 50.34 -161.64 0.06 Allowed 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.839 -0.619 . . . . 1.0 111.594 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 31.3 mtmm 53.58 91.63 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.08 -0.509 . . . . 1.0 111.08 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 51.9 p-10 . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 117.983 -1.008 . . . . 1.0 110.337 -179.986 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 72.8 mtp . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 108.888 -0.782 . . . . 1.0 108.888 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -65.38 -8.32 17.98 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.863 -0.608 . . . . 1.0 110.539 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -62.8 114.8 3.84 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-O 120.881 0.372 . . . . 1.0 110.264 -179.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 75.5 m-85 -85.89 140.0 30.76 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.981 -0.554 . . . . 1.0 109.7 178.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.1 p -65.12 -10.0 27.28 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.56 -0.746 . . . . 1.0 110.087 -179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.444 ' C ' ' H ' ' A' ' 8' ' ' LEU . 3.8 mp -98.1 138.73 21.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 114.924 -1.034 . . . . 1.0 109.665 -179.331 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 61.0 pttt -67.52 9.16 0.27 Allowed 'General case' 0 CA--C 1.535 0.366 0 CA-C-N 116.352 -0.385 . . . . 1.0 111.18 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.549 ' C ' HD12 ' A' ' 8' ' ' LEU . 3.1 pp -48.61 165.48 0.25 Allowed Pre-proline 0 CA--C 1.543 0.704 0 N-CA-C 112.349 0.5 . . . . 1.0 112.349 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.482 ' CD ' ' H ' ' A' ' 10' ' ' LYS . 49.7 Cg_endo -95.39 -51.41 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.364 0 C-N-CA 122.97 2.447 . . . . 1.0 109.393 178.716 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . 0.482 ' H ' ' CD ' ' A' ' 9' ' ' PRO . 60.3 pttt -167.58 32.01 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 114.972 -1.013 . . . . 1.0 108.64 178.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 40.6 t80 -55.66 -73.12 0.06 Allowed 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.185 -0.916 . . . . 1.0 111.357 -178.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.514 ' O ' HG12 ' A' ' 16' ' ' VAL . 92.9 mt -63.29 -38.85 92.76 Favored 'General case' 0 C--O 1.211 -0.932 0 N-CA-C 108.734 -0.839 . . . . 1.0 108.734 179.288 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -50.12 -52.62 26.3 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 121.243 -0.503 . . . . 1.0 112.818 -177.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.09 -39.34 27.66 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.686 -0.566 . . . . 1.0 111.686 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.417 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 95.6 mt -76.01 -56.85 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 112.357 0.503 . . . . 1.0 112.357 -178.218 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.514 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.8 OUTLIER -53.99 -31.4 21.06 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.464 0 CA-C-O 121.148 0.499 . . . . 1.0 110.889 -177.279 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 59.8 ttt85 -67.33 -36.62 81.82 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 108.392 -0.966 . . . . 1.0 108.392 178.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.417 ' HB3' ' O ' ' A' ' 15' ' ' ILE . . . -63.22 -39.52 94.86 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.046 -0.979 . . . . 1.0 109.466 179.08 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 9.8 mmt -60.11 -48.58 81.11 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.646 0.736 . . . . 1.0 109.568 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.0 mt -66.41 -41.66 88.97 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.411 -1.268 . . . . 1.0 109.795 179.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -74.21 -5.32 71.16 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.437 -0.801 . . . . 1.0 111.948 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 38.6 t -93.59 -30.94 14.72 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 121.716 0.769 . . . . 1.0 108.957 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.95 -45.78 33.22 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 114.27 -1.332 . . . . 1.0 108.751 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 85.8 mtt-85 48.34 17.0 0.11 Allowed 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 114.971 -1.013 . . . . 1.0 112.193 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -162.62 132.52 4.5 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.671 0.272 . . . . 1.0 110.442 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 61.3 t0 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.947 -1.025 . . . . 1.0 110.537 -179.776 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.2 mpt? . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 108.973 -0.751 . . . . 1.0 108.973 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -75.29 132.5 41.06 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.368 -0.378 . . . . 1.0 110.454 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.494 ' CD1' ' N ' ' A' ' 4' ' ' TYR . 46.3 p90 -143.32 -38.6 0.33 Allowed 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 120.899 0.381 . . . . 1.0 110.048 179.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.494 ' N ' ' CD1' ' A' ' 3' ' ' PHE . 34.3 p90 -62.7 166.14 5.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.02 -0.536 . . . . 1.0 110.833 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 70.6 p -127.03 20.99 6.88 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 121.802 0.81 . . . . 1.0 109.586 179.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.428 ' C ' ' H ' ' A' ' 8' ' ' LEU . 34.1 mt -113.35 147.65 16.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 114.241 -1.345 . . . . 1.0 109.079 -178.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -76.11 21.02 0.18 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-O 120.753 0.311 . . . . 1.0 110.77 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.52 HD13 ' H ' ' A' ' 11' ' ' PHE . 2.6 pp -59.39 167.25 2.4 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-N 116.302 -0.408 . . . . 1.0 111.503 -179.079 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -105.0 64.73 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 123.532 2.822 . . . . 1.0 110.913 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 97.6 mttt 54.95 55.81 7.33 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.274 0.559 . . . . 1.0 109.733 -178.464 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PHE . . . . . 0.52 ' H ' HD13 ' A' ' 8' ' ' LEU . 12.5 t80 -53.53 -78.79 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.471 -0.786 . . . . 1.0 111.091 -178.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.463 ' O ' HG12 ' A' ' 16' ' ' VAL . 85.8 mt -65.31 -38.13 89.23 Favored 'General case' 0 C--O 1.211 -0.938 0 N-CA-C 108.357 -0.979 . . . . 1.0 108.357 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.21 -52.67 22.1 Favored Glycine 0 CA--C 1.532 1.12 0 CA-C-N 115.95 -0.568 . . . . 1.0 112.61 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -77.85 -39.02 25.66 Favored Glycine 0 CA--C 1.531 1.046 0 CA-C-N 117.253 0.526 . . . . 1.0 112.037 179.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.6 mt -75.53 -55.76 10.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 112.042 0.386 . . . . 1.0 112.042 -178.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.463 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.4 OUTLIER -56.82 -30.0 31.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-O 120.741 0.305 . . . . 1.0 110.385 -177.202 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 32.7 tpt85 -65.35 -38.79 91.16 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.217 -1.031 . . . . 1.0 108.217 177.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.68 -39.05 92.75 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.273 -0.876 . . . . 1.0 109.592 179.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 22.6 mmt -60.36 -47.19 87.11 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.462 0.649 . . . . 1.0 109.359 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 92.8 mt -65.75 -41.6 91.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 114.806 -1.088 . . . . 1.0 109.584 178.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -59.35 -24.45 59.13 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.939 -0.865 . . . . 1.0 110.939 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.1 m -87.48 -35.28 18.32 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 121.285 0.564 . . . . 1.0 109.97 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -65.14 -48.53 73.22 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.09 -0.959 . . . . 1.0 111.677 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 42.5 mtm180 44.83 -159.59 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 115.986 -0.552 . . . . 1.0 111.883 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.0 mmtp -66.61 145.62 55.38 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.29 -0.414 . . . . 1.0 110.082 -179.609 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 68.7 m-20 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.035 -0.983 . . . . 1.0 110.726 -179.639 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.2 tpt . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 108.913 -0.773 . . . . 1.0 108.913 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -60.44 140.38 57.26 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 116.132 -0.486 . . . . 1.0 111.056 -179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 43.9 p90 -68.98 154.1 42.66 Favored 'General case' 0 CA--C 1.528 0.111 0 CA-C-N 116.008 -0.542 . . . . 1.0 110.172 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.409 ' C ' ' H ' ' A' ' 6' ' ' ILE . 76.3 m-85 -65.65 137.69 57.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.71 -0.677 . . . . 1.0 110.599 -179.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 29.8 p -63.5 -4.64 2.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.224 -0.898 . . . . 1.0 110.393 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.412 ' C ' ' H ' ' A' ' 8' ' ' LEU . 4.2 mp -103.5 137.62 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.125 -0.943 . . . . 1.0 109.299 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -79.24 31.37 0.22 Allowed 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 110.114 -0.328 . . . . 1.0 110.114 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.509 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.8 OUTLIER -52.95 167.64 0.39 Allowed Pre-proline 0 CA--C 1.549 0.904 0 CA-C-N 116.079 -0.509 . . . . 1.0 111.877 -178.612 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -102.55 5.92 0.44 Allowed 'Trans proline' 0 N--CA 1.487 1.117 0 C-N-CA 123.414 2.743 . . . . 1.0 110.206 179.086 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 25.1 mmtp 122.83 39.97 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 126.969 2.107 . . . . 1.0 107.886 -179.2 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -62.62 -69.15 0.28 Allowed 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.352 -0.84 . . . . 1.0 110.178 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.516 ' O ' HG12 ' A' ' 16' ' ' VAL . 89.6 mt -63.09 -34.88 78.56 Favored 'General case' 0 C--O 1.211 -0.951 0 N-CA-C 108.898 -0.779 . . . . 1.0 108.898 179.39 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.36 -52.6 22.97 Favored Glycine 0 CA--C 1.529 0.966 0 CA-C-N 116.116 -0.493 . . . . 1.0 113.13 -177.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -80.77 -39.94 13.07 Favored Glycine 0 CA--C 1.529 0.949 0 CA-C-N 117.491 0.645 . . . . 1.0 111.72 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.1 mt -72.48 -53.21 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 112.393 0.516 . . . . 1.0 112.393 -178.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.516 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.3 p -55.28 -30.98 25.87 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.504 0 C-N-CA 120.404 -0.518 . . . . 1.0 110.816 -177.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.6 mmt180 -66.53 -35.63 80.71 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 108.332 -0.988 . . . . 1.0 108.332 177.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.58 -39.36 94.19 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 115.577 -0.738 . . . . 1.0 109.459 178.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 10.4 mmt -60.18 -46.97 87.9 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.535 -0.757 . . . . 1.0 109.706 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.8 mt -66.27 -42.64 88.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.674 -1.148 . . . . 1.0 109.829 179.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -61.87 -24.27 64.44 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.43 -1.068 . . . . 1.0 110.43 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.4 m -88.83 -29.54 19.62 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.169 0.509 . . . . 1.0 109.855 179.415 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -66.35 -49.79 65.75 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 115.392 -0.822 . . . . 1.0 111.035 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 49.7 mtm-85 49.53 -178.89 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 115.538 -0.755 . . . . 1.0 111.857 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -65.39 135.96 55.9 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 115.96 -0.564 . . . . 1.0 110.345 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 41.2 p-10 . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 118.041 -0.981 . . . . 1.0 110.764 -179.976 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 43.0 tpp . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.155 -0.683 . . . . 1.0 109.155 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -148.62 145.48 27.79 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 109.451 -0.574 . . . . 1.0 109.451 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -161.23 175.35 12.41 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.016 0.436 . . . . 1.0 110.64 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 43.0 p90 -149.11 161.55 41.74 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.937 -0.574 . . . . 1.0 109.858 179.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.2 t -135.62 -5.03 2.25 Favored 'General case' 0 N--CA 1.48 1.047 0 CA-C-O 121.972 0.892 . . . . 1.0 108.989 179.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.8 mt -68.29 -3.89 2.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 113.89 -1.505 . . . . 1.0 109.867 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 48.4 mttt 52.36 30.03 7.59 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 114.867 -1.06 . . . . 1.0 109.257 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.528 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.5 OUTLIER -61.63 169.14 2.67 Favored Pre-proline 0 N--CA 1.443 -0.82 0 CA-C-N 113.406 -1.725 . . . . 1.0 111.705 -178.05 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -105.4 63.58 0.02 OUTLIER 'Trans proline' 0 N--CA 1.482 0.821 0 C-N-CA 123.569 2.846 . . . . 1.0 108.898 176.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt 58.26 45.82 16.61 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 115.299 -0.864 . . . . 1.0 111.01 -178.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -64.32 -73.8 0.11 Allowed 'General case' 0 N--CA 1.472 0.669 0 CA-C-O 121.301 0.572 . . . . 1.0 109.688 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.472 ' O ' HG12 ' A' ' 16' ' ' VAL . 87.3 mt -64.14 -34.59 78.41 Favored 'General case' 0 C--O 1.214 -0.774 0 CA-C-N 115.291 -0.868 . . . . 1.0 109.141 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -48.49 -50.15 24.97 Favored Glycine 0 CA--C 1.528 0.897 0 CA-C-N 116.153 -0.476 . . . . 1.0 112.814 -177.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.22 -41.93 9.01 Favored Glycine 0 CA--C 1.532 1.131 0 CA-C-N 117.468 0.634 . . . . 1.0 112.072 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.41 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 91.2 mt -72.05 -49.73 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 112.845 0.683 . . . . 1.0 112.845 -177.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.472 HG12 ' O ' ' A' ' 12' ' ' LEU . 1.4 p -55.38 -32.33 29.18 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.474 0 C-N-CA 120.45 -0.5 . . . . 1.0 111.1 -176.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 87.4 mtm180 -65.57 -35.2 80.15 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 108.31 -0.996 . . . . 1.0 108.31 177.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.41 ' HB3' ' O ' ' A' ' 15' ' ' ILE . . . -63.01 -39.13 93.82 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.525 -0.761 . . . . 1.0 109.304 179.24 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.6 mmt -60.77 -46.61 89.8 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.646 -0.706 . . . . 1.0 109.759 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.3 mt -65.52 -41.91 92.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 114.591 -1.186 . . . . 1.0 110.313 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.62 -27.92 61.96 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 110.401 -1.08 . . . . 1.0 110.401 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.2 t -73.24 -35.61 66.28 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.896 0.855 . . . . 1.0 109.257 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -61.07 -40.3 93.15 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.225 -1.352 . . . . 1.0 110.969 -178.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 24.0 mmm180 -54.08 -38.71 65.6 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.214 -0.448 . . . . 1.0 110.627 -178.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -62.81 136.86 58.08 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 109.798 -0.445 . . . . 1.0 109.798 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 26.5 t0 . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.847 -1.073 . . . . 1.0 111.051 -179.596 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.6 ttt . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 108.902 -0.777 . . . . 1.0 108.902 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 47.3 mmtm -67.11 131.76 46.46 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 109.571 -0.529 . . . . 1.0 109.571 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.458 ' CD1' ' N ' ' A' ' 4' ' ' TYR . 51.1 p90 -112.45 -42.0 3.76 Favored 'General case' 0 N--CA 1.478 0.946 0 C-N-CA 122.84 0.456 . . . . 1.0 110.482 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.458 ' N ' ' CD1' ' A' ' 3' ' ' PHE . 36.3 p90 -66.24 -35.64 80.95 Favored 'General case' 0 C--O 1.222 -0.382 0 CA-C-N 116.367 -0.379 . . . . 1.0 110.988 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.1 t 44.32 42.77 5.52 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 114.265 1.209 . . . . 1.0 114.265 178.058 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.412 HG22 ' H ' ' A' ' 8' ' ' LEU . 29.6 mt -133.78 144.49 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.781 -1.192 . . . . 1.0 107.781 179.22 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -72.84 17.48 0.12 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.063 0.394 . . . . 1.0 112.063 -178.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.586 HD13 ' H ' ' A' ' 11' ' ' PHE . 2.7 pp -62.08 168.84 3.32 Favored Pre-proline 0 CA--C 1.543 0.707 0 C-N-CA 122.862 0.465 . . . . 1.0 110.648 -179.679 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -104.21 64.1 0.02 OUTLIER 'Trans proline' 0 N--CA 1.491 1.373 0 C-N-CA 123.475 2.784 . . . . 1.0 111.802 -179.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 16.1 ttmm 58.31 54.91 5.35 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-O 121.174 0.511 . . . . 1.0 110.481 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PHE . . . . . 0.586 ' H ' HD13 ' A' ' 8' ' ' LEU . 9.0 t80 -59.93 -79.04 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 115.54 -0.754 . . . . 1.0 110.96 -179.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.485 ' O ' HG12 ' A' ' 16' ' ' VAL . 86.0 mt -65.1 -37.74 88.44 Favored 'General case' 0 C--O 1.212 -0.868 0 CA-C-N 115.576 -0.738 . . . . 1.0 109.015 -179.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -49.85 -45.85 40.33 Favored Glycine 0 CA--C 1.532 1.112 0 CA-C-N 115.997 -0.547 . . . . 1.0 112.688 -178.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -82.45 -41.34 9.19 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 111.607 -0.597 . . . . 1.0 111.607 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 95.4 mt -74.07 -54.85 13.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 112.121 0.415 . . . . 1.0 112.121 -178.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.485 HG12 ' O ' ' A' ' 12' ' ' LEU . 0.7 OUTLIER -56.65 -31.3 34.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.102 0.477 . . . . 1.0 110.703 -177.114 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -65.52 -37.05 85.62 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.66 -0.867 . . . . 1.0 108.66 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.84 -40.07 96.33 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.022 -0.99 . . . . 1.0 109.24 178.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' MET . . . . . . . . . . . . . 23.1 mmt -60.57 -47.26 86.99 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.519 -0.764 . . . . 1.0 109.81 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 96.0 mt -65.84 -40.57 91.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 114.68 -1.145 . . . . 1.0 109.989 179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -58.24 -26.92 59.64 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.726 -0.949 . . . . 1.0 110.726 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.9 m -87.42 -43.2 12.26 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 121.193 0.52 . . . . 1.0 110.344 179.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -66.75 -49.11 67.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.407 -0.815 . . . . 1.0 111.19 -178.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 52.9 mtp180 48.38 35.2 5.41 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.315 -0.857 . . . . 1.0 111.917 179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 68.3 mttm 53.3 41.51 32.12 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.24 -0.436 . . . . 1.0 111.106 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 36.6 t70 . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.209 -0.901 . . . . 1.0 110.421 179.942 . . . . . . . . 0 0 . 1 stop_ save_